1life Healthcare (ONEM) 10-Q 3 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Jul. 22, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-39203
Entity Registrant Name	1LIFE HEALTHCARE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	76-0707204
Entity Address, Address Line One	One Embarcadero Center
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94111
City Area Code	(415)
Local Phone Number	814-0927
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ONEM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		195,181,497
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001404123
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 184,748	$ 341,971
Short-term marketable securities	162,874	111,671
Accounts receivable, net	153,155	103,498
Inventories	6,571	6,065
Prepaid expenses	28,555	28,055
Other current assets	24,429	21,767
Total current assets	560,332	613,027
Long-term marketable securities	0	48,296
Restricted cash	3,785	3,801
Property and equipment, net	204,814	193,716
Right-of-use assets	272,966	256,293
Intangible assets, net	334,325	352,158
Goodwill	1,157,179	1,147,464
Other assets	7,518	12,277
Total assets	2,540,919	2,627,032
Current liabilities:
Accounts payable	17,046	18,725
Accrued expenses	76,289	72,672
Deferred revenue, current	57,651	47,928
Operating lease liabilities, current	36,465	31,152
Other current liabilities	29,030	31,632
Total current liabilities	216,481	202,109
Operating lease liabilities, non-current	291,596	269,641
Convertible senior notes	310,782	309,844
Deferred income taxes	60,199	73,875
Deferred revenue, non-current	25,768	29,317
Other non-current liabilities	11,611	13,663
Total liabilities	916,437	898,449
Commitments and contingencies (Note 13)
Stockholders' Equity:
Common stock, $0.001 par value, 1,000,000 and 1,000,000 shares authorized as of June 30, 2022 and December 31, 2021, respectively; 195,154 and 191,722 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	195	193
Additional paid-in capital	2,428,684	2,346,781
Accumulated deficit	(802,866)	(618,198)
Accumulated other comprehensive income	(1,531)	(193)
Total stockholders' equity	1,624,482	1,728,583
Total liabilities and stockholders' equity	$ 2,540,919	$ 2,627,032

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares, issued (in shares)	195,154,000	191,722,000
Common stock, shares, outstanding (in shares)	195,154,000	191,722,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net revenue:	$ 255,839	$ 120,416	$ 509,941	$ 241,768
Operating expenses:
Medical claims expense	108,900	0	213,866	0
Cost of care, exclusive of depreciation and amortization shown separately below	106,948	67,922	208,325	138,014
Sales and marketing	23,193	10,570	45,652	23,259
General and administrative	92,422	77,196	189,458	141,541
Depreciation and amortization	21,783	7,292	42,676	13,899
Total operating expenses	353,246	162,980	699,977	316,713
Loss from operations	(97,407)	(42,564)	(190,036)	(74,945)
Other income (expense), net:
Interest income	364	79	521	184
Interest and other expense	(3,682)	(2,842)	(8,801)	(5,685)
Total other income (expense), net	(3,318)	(2,763)	(8,280)	(5,501)
Loss before income taxes	(100,725)	(45,327)	(198,316)	(80,446)
Provision for (benefit from) income taxes	(6,916)	(4,040)	(13,648)	159
Net loss	$ (93,809)	$ (41,287)	$ (184,668)	$ (80,605)
Net loss per share — basic (in usd per share)	$ (0.48)	$ (0.30)	$ (0.95)	$ (0.59)
Net loss per share — diluted (in usd per share)	$ (0.48)	$ (0.30)	$ (0.95)	$ (0.59)
Weighted average common shares outstanding — basic (in shares)	194,488	136,788	193,774	137,045
Weighted average common shares outstanding — diluted (in shares)	194,488	136,788	193,774	137,045
Medicare revenue
Net revenue:	$ 131,594	$ 0	$ 259,016	$ 0
Commercial revenue
Net revenue:	$ 124,245	$ 120,416	$ 250,925	$ 241,768

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (93,809)	$ (41,287)	$ (184,668)	$ (80,605)
Other comprehensive loss:
Net unrealized gain (loss) on marketable securities	(305)	(12)	(1,338)	0
Comprehensive loss	$ (94,114)	$ (41,299)	$ (186,006)	$ (80,605)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect Period of Adoption Adjustment	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect Period of Adoption Adjustment	Accumulated Deficit	Accumulated Deficit Cumulative Effect Period of Adoption Adjustment	Accumulated Other Comprehensive Income (Loss)
Beginning balances (in shares) at Dec. 31, 2020			134,472
Beginning balances at Dec. 31, 2020	$ 548,475		$ 134	$ 918,118		$ (369,785)		$ 8
Beginning balances (ASU 2020-06) at Dec. 31, 2020		$ (66,737)			$ (73,393)		$ 6,656
Beginning balances (ASC 326) at Dec. 31, 2020		(428)					(428)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			2,584
Exercise of stock options	13,479		$ 3	13,476
Issuance of common stock for settlement of RSUs (in shares)			241
Stock-based compensation expense	26,328			26,328
Net unrealized (gain) loss on marketable securities	12							12
Net loss	(39,318)					(39,318)
Ending balances (in shares) at Mar. 31, 2021			137,297
Ending balances at Mar. 31, 2021	481,811		$ 137	884,529		(402,875)		20
Beginning balances (in shares) at Dec. 31, 2020			134,472
Beginning balances at Dec. 31, 2020	548,475		$ 134	918,118		(369,785)		8
Beginning balances (ASU 2020-06) at Dec. 31, 2020		(66,737)			$ (73,393)		6,656
Beginning balances (ASC 326) at Dec. 31, 2020		$ (428)					$ (428)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized (gain) loss on marketable securities	0
Net loss	(80,605)
Ending balances (in shares) at Jun. 30, 2021			137,774
Ending balances at Jun. 30, 2021	472,444		$ 138	916,460		(444,162)		8
Beginning balances (in shares) at Mar. 31, 2021			137,297
Beginning balances at Mar. 31, 2021	481,811		$ 137	884,529		(402,875)		20
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			353
Exercise of stock options	2,628		$ 1	2,627
Issuance of common stock under the employee stock purchase plan (in shares)			107
Issuance of common stock under the employee stock purchase plan	2,972			2,972
Issuance of common stock for settlement of RSUs (in shares)			17
Stock-based compensation expense	26,332			26,332
Net unrealized (gain) loss on marketable securities	(12)							(12)
Net loss	(41,287)					(41,287)
Ending balances (in shares) at Jun. 30, 2021			137,774
Ending balances at Jun. 30, 2021	472,444		$ 138	916,460		(444,162)		8
Beginning balances (in shares) at Dec. 31, 2021			191,722
Beginning balances at Dec. 31, 2021	1,728,583		$ 193	2,346,781		(618,198)		(193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			579
Exercise of stock options	2,235		$ 1	2,234
Issuance of common stock for settlement of RSUs (in shares)			442
Issuance of common stock in acquisition (in shares)			740
Stock-based compensation expense	36,919			36,919
Net unrealized (gain) loss on marketable securities	(1,033)							(1,033)
Net loss	(90,859)					(90,859)
Ending balances (in shares) at Mar. 31, 2022			193,483
Ending balances at Mar. 31, 2022	1,675,845		$ 194	2,385,934		(709,057)		(1,226)
Beginning balances (in shares) at Dec. 31, 2021			191,722
Beginning balances at Dec. 31, 2021	$ 1,728,583		$ 193	2,346,781		(618,198)		(193)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	1,403
Net unrealized (gain) loss on marketable securities	$ (1,338)
Net loss	(184,668)
Ending balances (in shares) at Jun. 30, 2022			195,154
Ending balances at Jun. 30, 2022	1,624,482		$ 195	2,428,684		(802,866)		(1,531)
Beginning balances (in shares) at Mar. 31, 2022			193,483
Beginning balances at Mar. 31, 2022	1,675,845		$ 194	2,385,934		(709,057)		(1,226)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			824
Exercise of stock options	3,215		$ 1	3,214
Issuance of common stock under the employee stock purchase plan (in shares)			234
Issuance of common stock under the employee stock purchase plan	1,659			1,659
Issuance of common stock for settlement of RSUs (in shares)			79
Issuance of common stock in acquisition (in shares)			534
Issuance of common stock in acquisition	5,541			5,541
Stock-based compensation expense	32,336			32,336
Net unrealized (gain) loss on marketable securities	(305)							(305)
Net loss	(93,809)					(93,809)
Ending balances (in shares) at Jun. 30, 2022			195,154
Ending balances at Jun. 30, 2022	$ 1,624,482		$ 195	$ 2,428,684		$ (802,866)		$ (1,531)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (93,809)	$ (90,859)	$ (41,287)	$ (39,318)	$ (184,668)	$ (80,605)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for bad debts					270	105
Depreciation and amortization	21,783		7,292		42,676	13,899
Amortization of debt discount and issuance costs					938	937
Accretion of discounts and amortization of premiums on marketable securities, net					661	483
Reduction of operating lease right-of-use assets					16,053	8,609
Stock-based compensation					69,255	52,660
Deferred income taxes					(13,676)	0
Other non-cash items					570	400
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable, net					(49,571)	11,380
Inventories					(481)	3,216
Prepaid expenses and other current assets					4,105	(21,261)
Other assets					3,792	110
Accounts payable					121	1,234
Accrued expenses					4,546	6,772
Deferred revenue					5,793	6,765
Operating lease liabilities					(13,143)	(8,761)
Other liabilities					(2,119)	17,128
Net cash (used in) provided by operating activities					(114,878)	13,071
Cash flows from investing activities:
Purchases of property and equipment, net					(34,188)	(31,172)
Purchases of marketable securities					(54,906)	(79,984)
Proceeds from sales and maturities of marketable securities					50,000	498,977
Acquisitions of businesses, net of cash and restricted cash acquired					(10,451)	(9,695)
Issuance of note receivable					0	(20,000)
Net cash (used in) provided by investing activities					(49,545)	358,126
Cash flows from financing activities:
Proceeds from the exercise of stock options					5,450	16,107
Proceeds from employee stock purchase plan					1,659	2,972
Payment of principal portion of finance lease liability					(27)	(29)
Net cash provided by financing activities					7,082	19,050
Net (decrease) increase in cash, cash equivalents and restricted cash					(157,341)	390,247
Cash, cash equivalents and restricted cash at beginning of period		$ 346,054		$ 115,005	346,054	115,005	$ 115,005
Cash, cash equivalents and restricted cash at end of period	$ 188,713		$ 505,252		188,713	505,252	$ 346,054
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses					7,732	5,883
Common stock and stock options assumed					$ 5,541	$ 0

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	Nature of the Business and Basis of Presentation 1Life Healthcare, Inc. (“1Life”) was incorporated in Delaware on July 25, 2002. 1Life’s headquarters are located in San Francisco, California. 1Life has developed a modernized healthcare membership model based on direct consumer enrollment and third-party sponsorship across commercially insured and Medicare populations. Our membership model includes access to 24/7 digital health services paired with in-office care routinely covered by most health care payers, and allows the Company to engage in value-based care across all age groups, including through At-Risk arrangements as defined in Note 2 “Summary of Significant Accounting Policies” with Medicare Advantage payers and the Center for Medicare & Medicaid Services ("CMS"), in which the Company is responsible for managing a range of healthcare services and associated costs of its members. 1Life is also an administrative and managerial services company that provides services pursuant to contracts with physician-owned professional corporations (“One Medical PCs”) that provide medical services virtually and in-office. On September 1, 2021, 1Life completed the acquisition of Iora Health, Inc. ("Iora Health"), a human-centered, value-based primary care group with built-for-purpose technology focused on serving the Medicare population. Iora Health and Iora Senior Health, Inc. (“Iora Senior Health”) are administrative and managerial service companies that provide services pursuant to contracts with physician-owned professional corporations (“Iora PCs”, together with the One Medical PCs, the “PCs”) that provide medical services virtually and in-office. Iora Health is an administrative and managerial services company that provides services pursuant to contracts with Iora Health NE DCE, LLC, a limited liability company that participates in the Center for Medicare and Medicaid Services’ Global and Professional Direct Contracting Model (the “DCE entity”). Iora Health, Iora Senior Health, the Iora PCs and the DCE entity are collectively referred to herein as “Iora”. See Note 7 "Business Combinations" to the unaudited condensed consolidated financial statements. 1Life, Iora Health, Iora Senior Health, the PCs and the DCE entity are collectively referred to herein as the “Company”. 1Life and the One Medical PCs operate under the brand name One Medical. Proposed Acquisition by Amazon As more fully described in Note 16, on July 20, 2022, the Company entered into a definitive merger agreement (the "Merger Agreement") with Amazon.com, Inc. ("Amazon"), pursuant to which (and subject to the terms and conditions described in the Merger Agreement) the Company will merge with and into a wholly-owned subsidiary of Amazon ("Amazon Merger"). Subject to the terms and conditions of the Merger Agreement, Amazon will acquire the Company for $18 per share in an all-cash transaction, valued at approximately $3.9 billion, including the Company’s net debt. As a result of the Amazon Merger, the Company will become a wholly-owned subsidiary of Amazon. The consummation of the Amazon Merger is subject to a number of closing conditions, including, among others, the approval from our shareholders, and the receipt of certain regulatory approvals, as well as other customary closing conditions. Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with U.S. GAAP. The accompanying condensed consolidated financial statements include the accounts of 1Life, Iora Health and Iora Senior Health, their wholly owned subsidiaries, and variable interest entities (“VIE”) in which 1Life, Iora Health and Iora Senior Health have an interest and are the primary beneficiaries. See Note 3, “Variable Interest Entities”. All significant intercompany balances and transactions have been eliminated in consolidation. In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly state its condensed consolidated financial position, results of operations, comprehensive loss and cash flows. The Company’s interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on February 23, 2022 (the “Form 10-K”). Use of Estimates The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and regulations of the SEC requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, liability for medical claims incurred in the period but not yet reported (“IBNR”), valuation of certain assets and liabilities acquired from business combinations, stock-based compensation, and determining the fair value of a reporting unit. Actual results could differ from these estimates and may result in material effects on the Company’s operating results and financial position. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there continues to be a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, allowance for credit losses, goodwill and other long-lived assets, and revenue recognition. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant from the Provider Relief Fund administered by the Department of Health and Human Services (“HHS”), which we recognized as Grant income during the six months ended June 30, 2021. The Company did not receive any income grant from the HHS for the three and six months ended June 30, 2022. See Note 5, "Revenue Recognition". Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consist of cash on deposit, investments in money market funds and commercial paper. Restricted cash represents cash held under letters of credit for various leases and certain At-Risk arrangements. The expected duration of restrictions on the Company’s restricted cash generally ranges from 1 to 8 years. The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the condensed consolidated statements of cash flows is as follows: June 30, December 31, June 30, December 31, 2022 2021 2021 2020 Cash and cash equivalents $ 184,748 $ 341,971 $ 503,238 $ 112,975 Restricted cash, current (included in other current assets) 180 282 119 119 Restricted cash, non-current 3,785 3,801 1,895 1,911 Total cash, cash equivalents, and restricted cash $ 188,713 $ 346,054 $ 505,252 $ 115,005 Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s marketable securities are invested in U.S. Treasury obligations and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. The Company grants unsecured credit to patients, most of whom reside in the service area of the One Medical or Iora facilities and are largely insured under third- party payer agreements. The Company’s concentration of credit risk is limited by the diversity, geography and number of patients and payers. The table below presents the customers or payers that individually represented 10% or more of the Company’s accounts receivable, net balance as of June 30, 2022 and December 31, 2021. June 30, December 31, 2022 2021 Customer F 45 % 38 % Customer I 17 % 23 % * Represents percentages below 10% of the Company’s accounts receivable in the period. The table below presents the customers or payers that individually represented 10% or more of the Company’s net revenue for the three and six months ended June 30, 2022 and 2021. Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Customer A * 12 % * 12 % Customer F * 12 % * 12 % Customer I 28 % N/A 27 % N/A Customer J 15 % N/A 17 % N/A * Represents percentages below 10% of the Company’s net revenue in the period.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The Company’s significant accounting policies are discussed in Note 2 “Summary of Significant Accounting Policies” in Item 15 of its Form 10-K for the fiscal year ended December 31, 2021. Recently Adopted Pronouncements as of June 30, 2022 In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the standard on January 1, 2022 on a prospective basis. The adoption did not have a material impact to the Company's condensed consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted as of June 30, 2022 There have been no recent accounting pronouncements or changes in accounting pronouncements that are of significance or potential significance to the Company as of June 30, 2022.

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities 1Life, Iora Health and Iora Senior Health's agreements with the PCs generally consist of both Administrative Services Agreements (“ASAs”), which provide for various administrative and management services to be provided by 1Life, Iora Health or Iora Senior Health, respectively, to the PCs, and succession agreements, which provide for transition of ownership of the PCs under certain conditions ("Succession Agreements"). The ASAs typically provide that the term of the arrangements is ten services including facilities, technology and intellectual property required for the day-to-day operation and management of each of the PCs, and makes recommendations to the PCs in establishing the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the agreements provide that 1Life, Iora Health and Iora Senior Health have the right to designate a person(s) to purchase the stock of the PCs for a nominal amount in the event of a succession event. Based upon the provisions of these agreements, 1Life determined that the PCs are variable interest entities due to its equity holder having insufficient capital at risk, and 1Life has a variable interest in the PCs. The contractual arrangement to provide management services allows 1Life, Iora Health or Iora Senior Health to direct the economic activities that most significantly affect the PCs. Accordingly, 1Life, Iora Health or Iora Senior Health is the primary beneficiary of the PCs and consolidates the PCs under the VIE model. Furthermore, as a direct result of nominal initial equity contributions by the physicians, the financial support 1Life, Iora Health or Iora Senior Health provides to the PCs (e.g. loans) and the provisions of the nominee shareholder succession arrangements described above, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the PCs. Therefore, all income and expenses recognized by the PCs are allocated to 1Life stockholders. The aggregate carrying value of the assets and liabilities included in the condensed consolidated balance sheets for the PCs after elimination of intercompany transactions and balances were $191,665 and $120,995, respectively, as of June 30, 2022 and $129,474 and $115,744, respectively, as of December 31, 2021.

Fair Value Measurements and Inv

Fair Value Measurements and Investments	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements and Investments	Fair Value Measurements and Investments Fair Value Measurements The following tables present information about the Company’s financial assets measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2022 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 116,118 $ — $ — $ 116,118 Short-term marketable securities: U.S. Treasury obligations 129,403 — — 129,403 Commercial paper — 33,471 — 33,471 Total financial assets $ 245,521 $ 33,471 $ — $ 278,992 Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 315,817 $ — $ — $ 315,817 Short-term marketable securities: U.S. Treasury obligations 58,232 — — 58,232 Foreign government bonds — 5,012 — 5,012 Commercial paper — 48,427 — 48,427 Long-term marketable securities: U.S. Treasury obligations 48,296 — — 48,296 Total financial assets $ 422,345 $ 53,439 $ — $ 475,784 Our financial assets are valued using market prices on both active markets (Level 1) and less active markets (Level 2). Level 1 instrument valuations are obtained from real-time quotes for transactions in active exchange markets involving identical assets. Level 2 instrument valuations are obtained from readily available pricing sources for comparable instruments, identical instruments in less active markets, or models using market observable inputs. During the three and six months ended June 30, 2022 and 2021, there were no transfers between Level 1, Level 2 and Level 3. Valuation of Convertible Senior Notes The Company has $316,250 aggregate principal amount outstanding of 3.0% convertible senior notes due in 2025 (the “2025 Notes”). See Note 9, “Convertible Senior Notes” for details. The fair value of the 2025 Notes was $262,858 and $288,461 as of June 30, 2022 and December 31, 2021, respectively. The fair value was determined based on the closing trading price of the 2025 Notes as of the last day of trading for the period. The fair value of the 2025 Notes is primarily affected by the trading price of the Company's common stock and market interest rates. The fair value of the 2025 Notes is considered a Level 2 measurement as they are not actively traded. Investments At June 30, 2022 and December 31, 2021, the Company’s cash equivalents and marketable securities were as follows: June 30, 2022 Amortized Gross Fair value Cash equivalents: Money market fund $ 116,118 $ — $ 116,118 Total cash equivalents 116,118 — 116,118 Short-term marketable securities: U.S. Treasury obligations 130,934 (1,531) 129,403 Commercial paper 33,471 — 33,471 Total short-term marketable securities 164,405 (1,531) 162,874 Total cash equivalents and marketable securities $ 280,523 $ (1,531) $ 278,992 December 31, 2021 Amortized Gross Fair value Cash equivalents: Money market fund $ 315,817 $ — $ 315,817 Total cash equivalents 315,817 — 315,817 Short-term marketable securities: U.S. Treasury obligations 58,293 (61) 58,232 Foreign government bonds 5,013 (1) 5,012 Commercial paper 48,427 — 48,427 Total short-term marketable securities 111,733 (62) 111,671 Long-term marketable securities: U.S. Treasury obligations 48,427 (131) 48,296 Total cash equivalents and marketable securities $ 475,977 $ (193) $ 475,784

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The following table summarizes the Company’s net revenue by primary source: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net revenue: Capitated revenue $ 128,521 $ — $ 253,151 $ — Fee-for-service and other revenue 3,073 — 5,865 — Total Medicare revenue 131,594 — 259,016 — Partnership revenue 63,401 56,126 124,336 111,057 Net fee-for-service revenue 35,740 43,416 77,254 87,878 Membership revenue 25,104 20,874 49,335 41,070 Grant income — — — 1,763 Total commercial revenue 124,245 120,416 250,925 241,768 Total net revenue $ 255,839 $ 120,416 $ 509,941 $ 241,768 Net fee-for-service revenue (previously reported as net patient service revenue) is primarily generated from commercial third-party payers with which the One Medical entities have established contractual billing arrangements. The following table summarizes net fee-for-service revenue by source: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net fee-for-service revenue: Commercial and government third-party payers $ 31,122 $ 39,608 $ 67,728 $ 81,843 Patients, including self-pay, insurance co-pays and deductibles 4,618 3,808 9,526 6,035 Net fee-for-service revenue $ 35,740 $ 43,416 $ 77,254 $ 87,878 The CARES Act was enacted on March 27, 2020 to provide economic relief to those impacted by the COVID-19 pandemic. The CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant of $1,763 from the Provider Relief Fund administered by the Health and Human Services ("HHS") during the six months ended June 30, 2021. The Company did not receive any income grants from the HHS for the three and six months ended June 30, 2022. Management has concluded that the Company met conditions of the grant funds and has recognized it as Grant income for the six months ended June 30, 2021. During the three and six months ended June 30, 2022, the Company recognized revenue of $25,021 and $32,448, which was included in the beginning deferred revenue balances as of April 1, 2022 and January 1, 2022, respectively. During the three and six months ended June 30, 2021, the Company recognized revenue of $20,041 and $26,187, which was included in the beginning deferred revenue balances as of April 1, 2021 and January 1, 2021, respectively. As of June 30, 2022, a total of $5,296 is included within deferred revenue related to variable consideration, of which $4,103 is classified as non-current as it will not be recognized within the next twelve months. The estimate of variable consideration is based on the Company’s assessment of historical, current, and forecasted performance. As summarized in the table below, the Company recorded contract assets and deferred revenue as a result of timing differences between the Company’s performance and the customer’s payment. June 30, December 31, 2022 2021 Balances from contracts with customers: Capitated accounts receivable, net $ 32,278 $ 23,903 All other accounts receivable, net 120,877 79,595 Contract asset (included in other current assets) 291 458 Deferred revenue $ 83,419 $ 77,245 Capitated accounts receivable and payable related to At-Risk arrangements are recorded net in the condensed consolidated balance sheets when a legal right of offset exists. A right of offset exists when all of the following conditions are met: 1) each of two parties (the Company and the third-party payer) owes the other determinable amounts; 2) the reporting party (the Company) has the right to offset the amount owed with the amount owed by the other party (the third-party payer); 3) the reporting party (the Company) intends to offset; and 4) the right of offset is enforceable by law. The capitated accounts receivable and payable are recorded at the contract level and consist of the Company’s Capitated Revenue attributed from enrolled At-Risk members less actual paid medical claims expense. If the Capitated Revenue exceeds the actual medical claims expense at the end of the reporting period, such surplus is recorded as capitated accounts receivable within accounts receivable, net in the condensed consolidated balance sheets. If the actual medical claims expense exceeds the Capitated Revenue, such deficit is recorded as capitated accounts payable within other current liabilities in the condensed consolidated balance sheets. As of June 30, 2022, the Company has capitated accounts receivable, net, of $32,278 and capitated accounts payable, net, of $1,680, representing amounts due from and to Medicare Advantage payers and CMS in At-Risk arrangements, respectively. The capitated accounts receivable and payable are presented net of IBNR claims liability and other adjustments. There were no significant prior period adjustments or changes to the assumptions used in estimating the IBNR claims liability as of June 30, 2022. The Company believes the amounts accrued to cover IBNR claims as of June 30, 2022 are adequate. Components of capitated accounts receivable, net is summarized below: June 30, December 31 2022 2021 Capitated accounts receivable $ 91,561 $ 56,384 IBNR claims liability (57,286) (32,320) Other adjustments (1,997) (161) Capitated accounts receivable, net $ 32,278 $ 23,903 Components of capitated accounts payable, net is summarized below: June 30, December 31 2022 2021 Capitated accounts (receivable), payable $ (6,245) $ 5,483 IBNR claims liability 7,761 1,438 Other adjustments 164 299 Capitated accounts payable, net $ 1,680 $ 7,220 Activity in IBNR claims liability from December 31, 2021 through June 30, 2022 is summarized below: Amount Balance as of December 31, 2021 $ 33,078 Incurred related to: Current period 215,332 Prior periods (1,466) 213,866 Paid related to: Current period (152,738) Prior periods (29,159) (181,897) Balance as of June 30, 2022 $ 65,047 The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of June 30, 2022, is expected to be recognized as follows: Less than Greater Total As of June 30, 2022 $ 15,193 $ 27,002 $ 42,195

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Leases Most leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 7 years. Certain lease agreements contain options to terminate the lease before maturity. The Company does not have any lease contracts with the option to purchase as of June 30, 2022. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases. Certain of the Company’s furniture and fixtures and lab equipment are held under finance leases. Finance-lease-related assets are included in property and equipment, net in the condensed consolidated balance sheets and are immaterial as of June 30, 2022. The components of operating lease costs were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating lease costs $ 13,609 $ 7,856 $ 26,613 $ 15,189 Variable lease costs 2,449 1,222 4,496 2,533 Total lease costs $ 16,058 $ 9,078 $ 31,109 $ 17,722 Other information related to leases was as follows: Supplemental Cash Flow Information Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12,398 $ 7,973 $ 24,464 $ 15,828 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 14,477 $ 19,336 $ 32,726 $ 35,422 Lease Term and Discount Rate June 30, December 31, 2022 2021 Weighted-average remaining lease term (in years) 7.96 8.02 Weighted-average discount rate 6.61 % 6.55 % At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate. Management determines the appropriate incremental borrowing rates for each of its leases based on the remaining lease term at lease commencement. Future minimum lease payments under non-cancellable operating leases as of June 30, 2022 were as follows (excluding the effect of lease incentives to be received that are recorded in other current assets of $16,353 which serve to reduce total lease payments): June 30, 2022 Remainder of 2022 $ 27,674 2023 58,264 2024 56,601 2025 52,821 2026 49,304 Thereafter 183,019 Total lease payments 427,683 Less: interest (99,622) Total lease liabilities $ 328,061

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business CombinationsAcquisition of Iora On September 1, 2021 ("Acquisition Date"), 1Life acquired all outstanding equity and capital stock of Iora Health, a human-centered, value-based primary care group with built-for-purpose technology focused on serving the Medicare population, for an aggregate purchase consideration of $1,424,836, which was paid through the issuance of 1Life common shares with a fair value of $1,313,312, in part by cash of $62,881, and in part by stock options of Iora assumed by 1Life towards pre-combination services of $48,643. The preliminary purchase price allocations resulted in $1,118,198 of goodwill and $363,031 of acquired identifiable intangible assets related to Iora trade name and contracts in existing geographies valued using the income method. Subsequent to the Acquisition Date, the Company recorded $285 and $2,085 to goodwill during the measurement period for the three and six months ended June 30, 2022. Goodwill recorded in the acquisition is not expected to be deductible for tax purposes. Goodwill was primarily attributable to the planned growth in new geographies, synergies expected to be achieved in the combined operations of 1Life and Iora, and assembled workforce of Iora. The acquisition expanded the Company's reach to become a premier national human-centered, technology-powered, value-based primary care platform across all age groups. The acquisition allows the Company to participate in At-Risk arrangements with Medicare Advantage payers and CMS, in which the Company is responsible for managing a range of healthcare services and associated costs of its members. Preliminary Purchase Price Allocation The purchase price components are summarized in the following table: Consideration in 1Life common stock (1) $ 1,313,312 Cash consideration (2) 62,881 Stock options of Iora assumed by 1Life towards pre-combination services (3) 48,643 Total Purchase Price $ 1,424,836 (1) Represents the fair value of 53,583 shares of 1Life common stock transferred as consideration consisting of 53,146 shares issued and 437 shares to be issued to former Iora shareholders for outstanding Iora capital stock based on 77,687 Iora shares with the Exchange Ratio of 0.69 for a share of Iora and 1Life's stock price of $24.51 as of the closing date. The fair value of the 53,583 shares transferred as consideration was determined on the basis of the closing market price of the Company's common stock one business day prior to the Acquisition Date. (2) Included in the cash consideration are: • $5,993 for the settlement of vested phantom stock awards and cash bonuses contingent on the completion of the merger. Iora's unvested phantom stock awards, to the extent they relate to post-combination services, will be paid out and expensed as they vest subsequent to the acquisition and will be treated as stock-based compensation expense. • $30,253 of loans made by the Company to Iora prior to the Acquisition Date. • $5,391 of repayment of the existing Silicon Valley Bank (“SVB”) loan, which was not legally assumed as part of the merger. • The remainder of the cash consideration primarily relates to transaction expenses incurred by Iora and paid by the Company as of the closing date. (3) Represents the fair value of Iora’s equity awards assumed by 1Life for pre-combination services. Pursuant to the terms of the Iora Merger Agreement, Iora’s outstanding equity awards that are vested and unvested as of the effective time of the merger were replaced by 1Life equity awards with the same terms and conditions. The vested portion of the fair value of 1Life’s replacement equity awards issued represents consideration transferred, while the unvested portion represents post-combination compensation expense based on the vesting terms of the equity awards. The awards that include a provision for accelerated vesting upon a change of control are included in the vested consideration. The fair value of the stock options of Iora assumed by 1Life was determined by using a Black-Scholes option pricing model with the applicable assumptions as of the Acquisition Date. The fair value of the unvested stock awards, for which post-combination service is required, will be recorded as share-based compensation expense over the respective vesting period of each award. See Note 10, "Stock-Based Compensation". The following table presents the preliminary purchase price allocation recorded in the Company's unaudited condensed consolidated balance sheet as of the Acquisition Date, updated to reflect measurement period adjustments as further described below: Cash and cash equivalents acquired $ 17,808 Accounts receivable, net 20,166 Prepaid expenses and other current assets 3,043 Restricted cash 2,069 Property and equipment, net 29,565 Right-of-use assets 70,249 Intangible assets, net 363,031 Other assets (1) 7,405 Total assets 513,336 Accounts payable 1,974 Accrued expenses 9,819 Deferred revenue, current 5,989 Operating lease liabilities, current 6,617 Operating lease liabilities, non-current 63,558 Deferred revenue, non-current 24,316 Deferred income taxes 80,537 Other non-current liabilities (1) 13,888 Total liabilities 206,698 Net assets acquired 306,638 Estimated merger consideration 1,424,836 Estimated goodwill attributable to merger $ 1,118,198 (1) Included in the other assets was an escrow asset of $2,034 related to 1Life common stock held by a third-party escrow agent to be released to the former stockholders of Iora, less any amounts that would be necessary to satisfy any then pending and unsatisfied or unresolved claim for indemnification for any 1Life indemnifiable loss pursuant to the indemnity provisions of the Iora Merger Agreement. A corresponding indemnification liability of $9,600 was recorded in other non-current liabilities in the Company's unaudited condensed consolidated balance sheet. During the six months ended June 30, 2022, a reduction in escrow asset and indemnification liability of $1,013 and $3,383, respectively was recorded as part of the measurement period adjustment. The indemnification asset is subject to remeasurement at each reporting date due to changes to the underlying value of the escrow shares until the shares are released from escrow, with the remeasurement adjustment reported in the Company's condensed consolidated statement of operations as interest and other expense. During the three and six months ended June 30, 2022, the fair value of the escrow asset had declined and the unrealized loss recorded was $841 and $3,118, respectively. The Company allocated the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on the preliminary estimates of fair values, which were determined primarily using the income method based on estimates and assumptions made by management at the time of the Iora acquisition and are subject to change during the measurement period which is not expected to exceed one year. The Company has completed the valuation of acquired intangible assets and is in the process of finalizing certain tax related liabilities. Any adjustments to the preliminary purchase price allocation identified during the measurement period will be recognized in the period in which the adjustments are determined. The Company recognized a net deferred tax liability of $80,537 in this business combination that is included in long-term liabilities in the accompanying condensed consolidated balance sheet. This primarily related to identified intangible assets recorded in acquisition for which there is no tax basis. Identifiable intangible assets are comprised of the following: Preliminary Fair Value Estimated Useful Life (in years) Intangible Asset: Medicare Advantage contracts - existing geographies $ 298,000 9 CMS Direct Contracting contract - existing geographies 52,000 9 Trade name: Iora 13,031 3 Total $ 363,031 Net tangible assets were valued at their respective carrying amounts as of the Acquisition Date, which approximated their fair values. Medicare Advantage contracts and CMS Direct Contracting contract represent the At-Risk arrangements that Iora has with Medicare Advantage plans or directly with CMS. Trade names represent the Company’s right to the Iora trade names and associated design. Loan Agreement Under the Iora Merger Agreement, 1Life and Iora have also entered into a Loan and Security Agreement on June 21, 2021. See Note 15 "Note Receivable" for more details. Iora had an existing credit facility with SVB, which is referred to as the SVB Facility. The SVB facility of $5,391 was repaid on September 1, 2021, of which $50 is related to the prepayment penalty. Repayment of the existing SVB loan is accounted for as part of the acquisition purchase consideration. Supplemental Unaudited Pro Forma Information The following unaudited pro forma financial information summarizes the combined results of operations for 1Life and Iora as if the companies were combined as of the beginning of fiscal year 2020. The unaudited pro forma information includes transaction and integration costs, adjustments to amortization and depreciation for intangible assets and property and equipment acquired, stock-based compensation costs and tax effects. The table below reflects the impact of material adjustments to the unaudited pro forma results for the three and six months ended June 30, 2021 that are directly attributable to the acquisition: Three Months Ended June 30, Six Months Ended June 30, Material Adjustments 2021 2021 (Decrease) / increase to expense as result of transaction costs $ (1,953) $ (5,190) (Decrease) / increase to expense as result of amortization and depreciation expenses 11,536 23,077 (Decrease) / increase to expense as a result of stock-based compensation costs 607 1,305 (Decrease) / increase to expense as result of changes in tax effects $ (3,144) $ (8,053) The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of our condensed consolidated results of operations of the combined business had the acquisition actually occurred at the beginning of fiscal year 2020 or the results of our future operations of the combined businesses. Three Months Ended June 30, Six Months Ended June 30, 2021 2021 Revenue $ 204,673 $ 388,293 Net Loss $ (74,752) $ (137,126) Other Acquisitions On April 14, 2022, the Company completed an acquisition for an aggregate purchase consideration of $17,354. The aggregate purchase consideration consisted of cash of $10,938, the issuance of 1Life common shares with a fair value of $5,541 and contingent consideration with a fair value of $875. The remaining purchase consideration consisted of the assumption of cash. The acquisition was accounted for as a business combination. The Company does not consider this acquisition to be material to the Company’s condensed consolidated financial statements. The preliminary purchase price allocation resulted in $11,800 of goodwill and $4,200 of acquired identifiable intangible assets related to customer relationships valued using the income approach. Intangible assets are being amortized over the useful lives of nine years. Acquisition-related costs were immaterial and were expensed as incurred in the condensed consolidated statements of operations. In 2021, the Company completed three other acquisitions for $9,908 of total cash consideration. The acquisitions were each accounted for as business combinations. The Company does not consider these acquisitions to be material, individually or in aggregate, to the Company’s condensed consolidated financial statements. The purchase price allocations resulted in $5,880 of goodwill and $3,921 of acquired identifiable intangible assets related to customer relationships valued using the income method. Intangible assets are being amortized over their respective useful lives of three

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill During the second quarter ended June 30, 2022, broadly in line with the stock market declines, the Company’s common stock declined significantly and dropped below its equity book value, which triggered a goodwill impairment analysis under FASB Topic 350 Intangibles – Goodwill and Other . For the purposes of the impairment analysis, goodwill is tested at the entity level as the Company has only one reporting unit. In determining the fair value of the reporting unit, the Company uses a combination of the income approach and the market approach, with each method weighted equally. Under the income approach, fair value is determined based on our estimates of future after-tax cash flows, discounted using the appropriate weighted average cost of capital. Under the market approach, the fair value is derived based on the valuation multiples of comparable publicly traded companies. As of June 30, 2022, the fair value of the reporting unit significantly exceeded its net book value. There was no impairment charge for the three and six months ended June 30, 2022 or 2021. The underlying valuation techniques deployed in the analysis are highly judgmental and entail significant estimates, including but not limited to, future growth and profitability, discount rates, and selection of peer companies and valuation multiples. Estimates are made based on the information available at the time of the valuation. Future changes in estimates and assumptions could result in material changes in the valuation. Goodwill balances as of June 30, 2022 and December 31, 2021 were as follows: Goodwill Balance as of December 31, 2021 $ 1,147,464 Goodwill recorded in connection with acquisition 11,800 Measurement period adjustments (2,085) Balance as of June 30, 2022 $ 1,157,179 Intangible Assets The following summarizes the Company’s intangible assets and accumulated amortization as of June 30, 2022: June 30, 2022 Original Cost Accumulated Amortization Net Book Value Medicare Advantage contracts - existing geographies $ 298,000 $ (27,593) $ 270,407 CMS Direct Contracting contract - existing geographies 52,000 (4,815) 47,185 Trade name: Iora 13,031 (3,620) 9,411 Customer relationships 8,121 (799) 7,322 Total intangible assets $ 371,152 $ (36,827) $ 334,325 The following summarizes the Company’s intangible assets and accumulated amortization as of December 31, 2021: December 31, 2021 Original Cost Accumulated Amortization Net Book Value Medicare Advantage contracts - existing geographies $ 298,000 $ (11,037) $ 286,963 CMS Direct Contracting contract - existing geographies 52,000 (1,926) 50,074 Trade name: Iora 13,031 (1,448) 11,583 Customer relationships 3,921 (383) 3,538 Total intangible assets $ 366,952 $ (14,794) $ 352,158 The Company recorded amortization expense of intangible assets of $11,074 and $22,033 for the three and six months ended June 30, 2022. The Company recorded amortization expense of intangible assets of $88 for the three and six months ended June 30, 2021. Purchased intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. As of June 30, 2022, estimated future amortization expense related to intangible assets were as follows: June 30, 2022 Remainder of 2022 $ 22,149 2023 44,297 2024 42,818 2025 39,880 2026 39,880 Thereafter 145,301 Total $ 334,325

Convertible Senior Notes

Convertible Senior Notes	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Convertible Senior Notes	Convertible Senior NotesIn May 2020, the Company issued and sold $275,000 aggregate principal amount of 3.0% convertible senior notes due 2025 in a private offering exempt from the registration requirements of the Securities Act of 1933, and in June 2020, the Company issued an additional $41,250 aggregate principal amount of such notes pursuant to the exercise in full of the over-allotment option by the initial purchasers of the notes (the “2025 Notes”). The 2025 Notes are unsecured obligations and bear interest at a fixed rate of 3.0% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2020. The 2025 Notes will mature on June 15, 2025, unless earlier converted, redeemed or repurchased. The total net proceeds from the debt offering, after deducting the initial purchasers’ commissions and other issuance costs, were $306,868. Each $1 principal amount of the 2025 Notes will initially be convertible into 0.0225052 shares of the Company’s common stock, which is equivalent to an initial conversion price of $44.43 per share, subject to adjustment upon the occurrence of specified events but not for any accrued and unpaid interest. Holders may convert the 2025 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined below) per $1 principal amount of the 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls such 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. It is the Company’s current intent to settle conversions through combination settlement comprising of cash and equity. On or after March 15, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their 2025 Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election and in accordance with the terms of the indenture governing the 2025 Notes. If the Company satisfies its conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, the amount of cash and shares of common stock, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 40 trading day observation period. In addition, following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2025 Notes in connection with such a corporate event or notice of redemption, as the case may be. If the Company undergoes a fundamental change prior to the maturity date, holders of the 2025 Notes may require the Company to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. If consummated, the Amazon Merger is expected to constitute both a “fundamental change” and a “make-whole fundamental change” (each as defined in the indenture governing the 2025 Notes). Upon the occurrence of a fundamental change, holders of the 2025 Notes may convert their 2025 Notes for a period and, subject to limited exceptions, may require the Company to repurchase for cash all or any portion of their 2025 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. With respect to a make-whole fundamental change, the $18 per share purchase price in the Amazon Merger is below the lowest stock price on the “make-whole” table included in the indenture governing the 2025 Notes and converting holders of the 2025 Notes will not receive additional conversion consideration in connection with any conversion of their 2025 Notes as a result of the make-whole fundamental change. In addition, if specific corporate events occur prior to the applicable maturity date, the Company will increase the conversion rate for a holder who elects to convert their 2025 Notes in connection with such a corporate event in certain circumstances. The Company may not redeem the 2025 Notes prior to June 20, 2023. The Company may redeem for cash all or any portion of the 2025 Notes, at the Company’s option, on or after June 20, 2023 and prior to March 15, 2025, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the notes. During the three months ended June 30, 2022, the conditions allowing holders of the 2025 Notes to convert have not been met. The 2025 Notes are therefore not convertible as of June 30, 2022 and are classified in long term liabilities in the condensed consolidated balance sheet. The Company incurred issuance costs of $9,374 and amortizes the issuance costs to interest expense over the contractual term of the 2025 Notes at an effective interest rate of 0.65%. The net carrying amount of the 2025 Notes was as follows: June 30, December 31, 2022 2021 Liabilities: Principal $ 316,250 $ 316,250 Unamortized issuance costs (5,468) (6,406) Net carrying amount $ 310,782 $ 309,844 The following table sets forth the interest expense recognized related to the 2025 Notes: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Contractual interest expense $ 2,372 $ 2,372 $ 4,744 $ 4,744 Amortization of issuance costs 468 468 937 937 Total interest expense related to the 2025 Notes $ 2,840 $ 2,840 $ 5,681 $ 5,681

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Incentive Plan The Company has the following stock-based compensation plans: the 2007 Equity Incentive Plan (the “2007 Plan”), the 2017 Equity Incentive Plan (the “2017 Plan”), and the 2020 Equity Incentive Plan (the “2020 Plan”, and, together with the 2007 Plan and the 2017 Plan, the “Plans”). In January 2020, the Company’s stockholders approved the 2020 Plan, which took effect upon the execution of the underwriting agreement for the Company’s IPO in January 2020. The 2020 Plan is intended as the successor to and continuation of the 2007 Plan and the 2017 Plan. The number of shares of common stock reserved for issuance under the Company’s 2020 Plan will automatically increase on January 1 of each year, beginning on January 1, 2021, and continuing through and including January 1, 2030, by 4% of the total number of shares of common stock outstanding on December 31 of the immediately preceding calendar year, or a lesser number of shares determined by the Company’s board prior to the applicable January 1st. The number of shares issuable under the Plans is adjusted for capitalization changes, forfeitures, expirations and certain share reacquisitions. The Plan provides for the grants of incentive stock options (“ISOs”), non-statutory stock options (“NSOs”), restricted stock awards, and restricted stock unit awards (“RSUs”). ISOs may be granted only to employees, including officers. All other awards may be granted to employees, including officers, non-employee directors and consultants. The 2020 Plan provides that grants of ISOs will be made at no less than the estimated fair value of common stock, as determined by the Board of Directors, at the date of grant. Stock options granted to employees and nonemployees under the Plans generally vest over 4 years. Options granted under the Plans generally expire 10 years after the date of grant. At June 30, 2022, 6,975 shares were available for future grants. 2020 Employee Stock Purchase Plan In January 2020, the Company’s stockholders approved the 2020 Employee Stock Purchase Plan (“ESPP”), which became effective upon the execution of the underwriting agreement for the Company’s IPO in January 2020. The ESPP provides for separate six-month offering periods beginning on May 16 and November 16 of each year. At June 30, 2022, 7,046 shares were available for future issuance. The stock-based compensation expense recognized for the ESPP was $177 and $602 during the three and six months ended June 30, 2022 and $591 and $1,212 during the three and six months ended June 30, 2021, respectively. Stock Options The following table summarizes stock option activity under the Plans: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2021 28,312 $ 19.32 7.57 $ 192,955 Granted 1,819 12.11 Exercised (1,403) 3.88 Canceled (630) 14.57 Outstanding as of June 30, 2022 28,098 $ 19.73 7.26 $ 37,185 Options exercisable as of June 30, 2022 12,228 $ 6.34 5.84 $ 35,355 Options vested and expected to vest as of June 30, 2022 18,179 $ 8.85 6.59 $ 37,157 At June 30, 2022 and 2021, there was $19,403 and $14,805, respectively, in unrecognized compensation expense related to service-based options, net of forfeitures, that is expected to be recognized over a weighted-average period of 1.5 and 1.8 years, respectively. The fair value of stock option grants with service-based vesting conditions was $11,598 for the three and six months ended June 30, 2022, and $50 and $12,218, respectively, for the three and six months ended June 30, 2021. Assumed Equity Awards As of the Acquisition Date, the Company assumed Iora’s outstanding equity awards related to stock options and phantom stock. The awards under the assumed equity plan were generally settled as follows: • Options: All Iora options outstanding on the close date were assumed by 1Life and converted into options to acquire shares of 1Life common stock. The vested and unvested options, to the extent related to pre-combination services were included in the consideration transferred. Iora’s unvested options, to the extent they relate to post-combination services, will be expensed as they vest post the acquisition and will be treated as stock-based compensation expense. See Note 7 "Business Combinations". • Phantom stock: Each Iora vested phantom stock award has been settled in cash. Each Iora unvested phantom stock award has been assumed by the Company and converted into the right to receive the unvested phantom cash award. Each unvested phantom cash award will remain subject to the same terms and conditions as were applicable to the underlying unvested phantom stock award immediately prior to the close date. The unvested phantom stock award is considered a liability-classified award as the settlement involves a cash payment upon the dates when these awards vest. The entire vested award and unvested phantom stock, to the extent they relate to pre-combination services, were included in the consideration transferred. Iora’s unvested phantom stock awards, to the extent they relate to post-combination services, will be expensed as they vest post acquisition and will be treated as stock-based compensation expense. See Note 7 "Business Combinations". As of the Acquisition Date, the estimated fair value of the assumed equity awards was $60,856, of which $52,662 was allocated to the purchase price and the balance of $8,194 will be recognized as stock-based compensation expense over the remainder term of the assumed equity awards. The fair value of the assumed equity awards for service rendered through the Acquisition Date was recognized as a component of the acquisition consideration, with the remaining fair value related to post combination services to be recorded as stock-based compensation over the remaining vesting period. Market-based Stock Options During the year ended December 31, 2020, the Board of Directors (“Board”) approved the grant of a long-term market-based stock option (the “Performance Stock Option”) to the Company’s Chief Executive Officer and President. The Performance Stock Option was granted to acquire up to 8,645 shares of the Company’s common stock upon exercise. The Performance Stock Option consists of four separate tranches and each tranche will vest over a seven-year time period and only if the Company’s stock price sustains achievement of pre-determined increases for a period of 90 consecutive calendar days and the Chief Executive Officer remains employed with the Company. The exercise price per share of the Stock Option is the closing price of a share of the Company’s common stock on the date of grant. The vesting of the Performance Stock Option can also be triggered upon a change in control. The following table presents additional information relating to each tranche of the Performance Stock Option: Tranche Stock Price Milestone Number of Options Tranche 1 $55 per share 1,330 Tranche 2 $70 per share 1,995 Tranche 3 $90 per share 2,660 Tranche 4 $110 per share 2,660 As of June 30, 2022, no stock price milestones have been achieved. Consequently, no shares subject to the Performance Stock Option have vested as of the date of this filing. The entire 8,645 shares granted are excluded from options vested and expected to vest from the options activity table presented above. The Company will recognize aggregate stock-based compensation expense of $197,469 over the derived service period of each tranche using the accelerated attribution method as long as the service-based vesting conditions are satisfied. If the market conditions are achieved sooner than the derived service period, the Company will adjust its stock-based compensation to reflect the cumula tive expense associated with the vested awards. The Company recorded stock-based compensation expense of $13,661 and $27,750 related to the award for the three and six months ended June 30, 2022, which is included in general and administrative on the condensed consolidated statements of operations. Unamortized stock-based compensation expense related to the award was $109,202 as of June 30, 2022. Restricted Stock Units The following table summarizes restricted stock unit activity under the 2020 Plan: Number of Grant Date Unvested and outstanding as of December 31, 2021 3,249 $ 27.90 Granted 8,929 9.83 Vested (521) 31.94 Canceled and forfeited (734) 17.56 Unvested and outstanding as of June 30, 2022 10,923 $ 13.63 Stock-Based Compensation Expense Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Sales and marketing $ 1,325 $ 964 $ 2,268 $ 1,987 General and administrative 31,011 25,368 66,987 50,673 Total $ 32,336 $ 26,332 $ 69,255 $ 52,660 A tax benefit of $797 and $2,735 for the three and six months ended June 30, 2022, respectively, and $2,248 and $32,642 for the three and six months ended June 30, 2021, respectively, was included in the Company’s net operating loss carry-forward that could potentially reduce future tax liabilities.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe Company recorded an income tax benefit of $6,916 and $4,040 for the three months ended June 30, 2022 and 2021, respectively. This represents an effective tax rate for the respective periods of 6.9% and 8.9%, respectively. The Company reassessed the ability to realize deferred tax assets by considering the available positive and negative evidence. As of June 30, 2022, the Company maintains a full valuation allowance against its net deferred tax assets. Amortization of book identified intangibles from the Iora acquisition resulted in a decrease to deferred tax liabilities; the associated income tax benefit during the period was $6,930. The effective tax rate differs in 2022 from the federal statutory rate due to the change in need for valuation allowance and amortization of identified intangibles. The effective tax rate differs in 2021 from the federal statutory rate due to increased taxable income in profitable entities and the change in need for valuation allowance.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic and diluted net loss per share were calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss $ (93,809) $ (41,287) $ (184,668) $ (80,605) Denominator: Weighted average common shares outstanding — basic and diluted 194,488 136,788 193,774 137,045 Net loss per share — basic and diluted $ (0.48) $ (0.30) $ (0.95) $ (0.59) The Company’s potentially dilutive securities, which include stock options, unvested RSUs, 2025 Notes and shares held in special indemnity escrow account in connection with Iora acquisition, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: As of June 30, 2022 2021 Options to purchase common stock 28,098 25,754 Unvested restricted stock 10,922 2,053 2025 Notes (1) 7,117 7,117 Shares held in special indemnity escrow account in connection with Iora acquisition 405 — 46,542 34,924

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of June 30, 2022 and December 31, 2021, the Company has not incurred any material costs as a result of such indemnifications. Legal Matters In May 2018, a class action complaint was filed by two former members against the Company in the Superior Court of California for the County of San Francisco, or the Court, alleging that the Company made certain misrepresentations resulting in them paying the Annual Membership Fee, or AMF, in violation of California’s Consumers Legal Remedies Act, California’s False Advertising Law and California’s Unfair Competition Law, and seeking damages and injunctive relief. Following certain trial court proceedings and certain appeals, arbitration proceedings, and court-ordered mediation proceedings, in June 2021, the parties filed a joint notice of settlement and request for stay before the appellate court in light of reaching a settlement in principle. The parties later executed a class action settlement agreement and release effective June 30, 2021, which requires trial court approval. A preliminary class settlement approval hearing was scheduled to take place in August 2021, but the trial court requested supplemental briefing and vacated the previously scheduled hearing. Plaintiffs filed their supplemental brief and supporting documents on October 12, 2021. The trial court granted the motion for preliminary approval on November 12, 2021. Pursuant to the terms of the settlement and the trial court’s order, the class notice phase took place in late February 2022. The final approval hearing for the settlement was held on July 25, 2022. On July 26, 2022, the court granted the motion for final approval of the class action settlement. A compliance hearing is currently scheduled for March 2, 2023. The settlement amount of $11,500 was recorded as other current liabilities in the condensed consolidated balance sheets as of June 30, 2021. The Company's insurers committed to pay $5,950 towards the settlement amount. The settlement amount, net of expected insurance recovery, of which $5,550 was recorded as general and administrative expenses in the condensed consolidated statements of operations for the three months ended June 30, 2021. Class payout is expected to occur in 2022. There was no material change to the liability amount or any incremental expenses incurred during the three months ended June 30, 2022. Government Inquiries and Investigations In March 2021, the Company received (i) requests for information and documents from the United States House Select Subcommittee on the Coronavirus Crisis, (ii) a request for information from the California Attorney General and the Alameda County District Attorney’s Office and (iii) a request for information and documents from the Federal Trade Commission relating to the Company’s provision of COVID-19 vaccinations. The Company has also received inquiries from state and local public health departments regarding its vaccine administration practices and has and may continue to receive additional requests for information from other governmental agencies relating to its provision of COVID-19 vaccinations. The Company is cooperating with these requests as well as requests received from other governmental agencies, including with respect to the Company's compensation practices and membership generation during the relevant periods. The majority staff of the Subcommittee released a memorandum of findings in December 2021. No further disclosures, testimony or other responses have been requested by the Subcommittee. In addition, in February 2022, the Federal Trade Commission advised us that they were closing their inquiry on our provision of COVID-19 vaccinations. The Company is unable to predict the outcomes or timeline of the residual government inquiries or if any additional requests, inquiries, investigations or other government actions may arise relating to such circumstances. Legal fees have been recorded as general and administrative expenses in the consolidated statements of operations. Sales and Use Tax During 2017 and 2018, a state jurisdiction engaged in an audit of 1Life’s sales and use tax records applicable to that jurisdiction from March 2011 through February 2017. The Company disputed the finding representing the majority of the state's proposed audit change and successfully overturned the sales tax assessment resulting from the audit in December 2021. The audit was closed and the payment, which was not material, was remitted during the first quarter ended March 31, 2022. In addition, from time to time, the Company has been and may be involved in various legal proceedings arising in the ordinary course of business. The Company currently believes that the outcome of these legal proceedings, either individually or in the aggregate, will not have a material effect on its consolidated financial position, results of operations or cash flows.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party TransactionsCertain of the Company’s investors are also affiliated with customers of the Company. Revenue recognized under contractual obligations from such customers was immaterial for the three and six months ended June 30, 2022 and June 30, 2021, respectively. The outstanding receivable balance from such customers was immaterial as of June 30, 2022 and December 31, 2021, respectively.

Note Receivable

Note Receivable	6 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Note Receivable	Note ReceivableIn connection with the Iora acquisition, on June 21, 2021, 1Life and Iora entered into a loan agreement under which the Company may advance secured loans to Iora to fund working capital, at Iora's request from time to time, in outstanding amounts not to exceed $75,000 in the aggregate. Amounts drawn under the loan agreement are secured by all assets of Iora and were subordinated to Iora's obligations under its then-existing credit facility with SVB. The loan agreement is effective through the maturity date of borrowed amounts under the loan agreement. Such maturity date is the later of 90 days following the earliest of certain maturity dates set forth in the SVB Facility. Amounts drawn bear interest at a rate equal to 10% per year, payable monthly. As of the Acquisition Date, there was $30,000 drawn and outstanding under the loan agreement. Pursuant to the consummation of Iora's acquisition by 1Life, this note receivable was eliminated as part of intercompany eliminations. $30,253 of note receivable including accrued interests prior to the Acquisition Date was treated as purchase consideration. See Note 7 "Business Combinations" for additional details.

Proposed Acquisition by Amazon

Proposed Acquisition by Amazon	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Proposed Acquisition by Amazon	Proposed Acquisition by Amazon On July 20, 2022, the Company entered into the Merger Agreement with Amazon. Subject to the terms and conditions of the Merger Agreement, Amazon will acquire the Company for $18 per share in an all-cash transaction valued at approximately $3.9 billion, including the Company’s net debt. As a result of the Amazon Merger, the Company will become a wholly-owned subsidiary of Amazon. The consummation of the Amazon Merger is subject to a number of closing conditions, including, among others, the approval from our shareholders, and the receipt of certain regulatory approvals, as well as other customary closing conditions. Under the Merger Agreement, Amazon has agreed to provide senior unsecured interim debt financing to the Company in an aggregate principal amount of up to $300.0 million to be funded in up to ten tranches of $30.0 million per month, beginning on March 20, 2023 until the earlier of the closing of the Amazon Merger and the termination of the Merger Agreement pursuant to its terms, with a maturity date of 24 months after the termination of the Merger Agreement pursuant to its terms. The Company will agree to certain restrictive covenants and events of default customary for transactions of this type in connection with the debt financing, and other terms and conditions to be set forth in definitive agreements to be entered into by the parties in connection with the financing.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Pursuant to these rules and regulations, the Company has condensed or omitted certain information and footnote disclosures it normally includes in its annual consolidated financial statements prepared in accordance with U.S. GAAP. The accompanying condensed consolidated financial statements include the accounts of 1Life, Iora Health and Iora Senior Health, their wholly owned subsidiaries, and variable interest entities (“VIE”) in which 1Life, Iora Health and Iora Senior Health have an interest and are the primary beneficiaries. See Note 3, “Variable Interest Entities”. All significant intercompany balances and transactions have been eliminated in consolidation. In management’s opinion, the Company has made all adjustments (consisting only of normal, recurring adjustments, except as otherwise indicated) necessary to fairly state its condensed consolidated financial position, results of operations, comprehensive loss and cash flows. The Company’s interim period operating results do not necessarily indicate the results that
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and regulations of the SEC requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates include, but are not limited to, revenue recognition, liability for medical claims incurred in the period but not yet reported (“IBNR”), valuation of certain assets and liabilities acquired from business combinations, stock-based compensation, and determining the fair value of a reporting unit. Actual results could differ from these estimates and may result in material effects on the Company’s operating results and financial position. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there continues to be a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, allowance for credit losses, goodwill and other long-lived assets, and revenue recognition. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant from the Provider Relief Fund administered by the Department of Health and Human Services (“HHS”), which we recognized as Grant income during the six months ended June 30, 2021. The Company did not receive any income grant from the HHS for the three and six months ended June 30, 2022. See Note 5, "Revenue Recognition".
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consist of cash on deposit, investments in money market funds and commercial paper. Restricted cash represents cash held under letters of credit for various leases and certain At-Risk arrangements. The expected duration of restrictions on the Company’s restricted cash generally ranges from 1 to 8 years.
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s marketable securities are invested in U.S. Treasury obligations and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. The Company grants unsecured credit to patients, most of whom reside in the service area of the One Medical or Iora facilities and are largely insured under third-
Recently Adopted Pronouncements as of June 30, 2022	Recently Adopted Pronouncements as of June 30, 2022 In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance which requires annual disclosures that increase the transparency of transactions involving government grants, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted the standard on January 1, 2022 on a prospective basis. The adoption did not have a material impact to the Company's condensed consolidated financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted as of June 30, 2022	Recently Issued Accounting Pronouncements Not Yet Adopted as of June 30, 2022 There have been no recent accounting pronouncements or changes in accounting pronouncements that are of significance or potential significance to the Company as of June 30, 2022.

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reconciliation of Cash, Cash Equivalents and Restricted Cash	The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the condensed consolidated statements of cash flows is as follows: June 30, December 31, June 30, December 31, 2022 2021 2021 2020 Cash and cash equivalents $ 184,748 $ 341,971 $ 503,238 $ 112,975 Restricted cash, current (included in other current assets) 180 282 119 119 Restricted cash, non-current 3,785 3,801 1,895 1,911 Total cash, cash equivalents, and restricted cash $ 188,713 $ 346,054 $ 505,252 $ 115,005
Summary of Customers Representing 10% or More of Accounts Receivables	The table below presents the customers or payers that individually represented 10% or more of the Company’s accounts receivable, net balance as of June 30, 2022 and December 31, 2021. June 30, December 31, 2022 2021 Customer F 45 % 38 % Customer I 17 % 23 % * Represents percentages below 10% of the Company’s accounts receivable in the period.
Summary of Customers Representing 10% or More of Net Revenue	The table below presents the customers or payers that individually represented 10% or more of the Company’s net revenue for the three and six months ended June 30, 2022 and 2021. Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Customer A * 12 % * 12 % Customer F * 12 % * 12 % Customer I 28 % N/A 27 % N/A Customer J 15 % N/A 17 % N/A * Represents percentages below 10% of the Company’s net revenue in the period.

Fair Value Measurements and I_2

Fair Value Measurements and Investments (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2022 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 116,118 $ — $ — $ 116,118 Short-term marketable securities: U.S. Treasury obligations 129,403 — — 129,403 Commercial paper — 33,471 — 33,471 Total financial assets $ 245,521 $ 33,471 $ — $ 278,992 Fair Value Measurements as of December 31, 2021 Using: Level 1 Level 2 Level 3 Total Cash equivalents: Money market fund $ 315,817 $ — $ — $ 315,817 Short-term marketable securities: U.S. Treasury obligations 58,232 — — 58,232 Foreign government bonds — 5,012 — 5,012 Commercial paper — 48,427 — 48,427 Long-term marketable securities: U.S. Treasury obligations 48,296 — — 48,296 Total financial assets $ 422,345 $ 53,439 $ — $ 475,784
Components of Cash Equivalents and Short-term Marketable Securities	At June 30, 2022 and December 31, 2021, the Company’s cash equivalents and marketable securities were as follows: June 30, 2022 Amortized Gross Fair value Cash equivalents: Money market fund $ 116,118 $ — $ 116,118 Total cash equivalents 116,118 — 116,118 Short-term marketable securities: U.S. Treasury obligations 130,934 (1,531) 129,403 Commercial paper 33,471 — 33,471 Total short-term marketable securities 164,405 (1,531) 162,874 Total cash equivalents and marketable securities $ 280,523 $ (1,531) $ 278,992 December 31, 2021 Amortized Gross Fair value Cash equivalents: Money market fund $ 315,817 $ — $ 315,817 Total cash equivalents 315,817 — 315,817 Short-term marketable securities: U.S. Treasury obligations 58,293 (61) 58,232 Foreign government bonds 5,013 (1) 5,012 Commercial paper 48,427 — 48,427 Total short-term marketable securities 111,733 (62) 111,671 Long-term marketable securities: U.S. Treasury obligations 48,427 (131) 48,296 Total cash equivalents and marketable securities $ 475,977 $ (193) $ 475,784

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Net Revenue	The following table summarizes the Company’s net revenue by primary source: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net revenue: Capitated revenue $ 128,521 $ — $ 253,151 $ — Fee-for-service and other revenue 3,073 — 5,865 — Total Medicare revenue 131,594 — 259,016 — Partnership revenue 63,401 56,126 124,336 111,057 Net fee-for-service revenue 35,740 43,416 77,254 87,878 Membership revenue 25,104 20,874 49,335 41,070 Grant income — — — 1,763 Total commercial revenue 124,245 120,416 250,925 241,768 Total net revenue $ 255,839 $ 120,416 $ 509,941 $ 241,768
Summary of Net Patient Service Revenue by Source	The following table summarizes net fee-for-service revenue by source: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net fee-for-service revenue: Commercial and government third-party payers $ 31,122 $ 39,608 $ 67,728 $ 81,843 Patients, including self-pay, insurance co-pays and deductibles 4,618 3,808 9,526 6,035 Net fee-for-service revenue $ 35,740 $ 43,416 $ 77,254 $ 87,878
Schedule of Contract Assets and Deferred Revenue	As summarized in the table below, the Company recorded contract assets and deferred revenue as a result of timing differences between the Company’s performance and the customer’s payment. June 30, December 31, 2022 2021 Balances from contracts with customers: Capitated accounts receivable, net $ 32,278 $ 23,903 All other accounts receivable, net 120,877 79,595 Contract asset (included in other current assets) 291 458 Deferred revenue $ 83,419 $ 77,245
Schedule of Capitated Accounts Receivable, Net	Components of capitated accounts receivable, net is summarized below: June 30, December 31 2022 2021 Capitated accounts receivable $ 91,561 $ 56,384 IBNR claims liability (57,286) (32,320) Other adjustments (1,997) (161) Capitated accounts receivable, net $ 32,278 $ 23,903
Schedule of Capitated Accounts Payable	Components of capitated accounts payable, net is summarized below: June 30, December 31 2022 2021 Capitated accounts (receivable), payable $ (6,245) $ 5,483 IBNR claims liability 7,761 1,438 Other adjustments 164 299 Capitated accounts payable, net $ 1,680 $ 7,220
Activity in IBNR Claims Liability	Activity in IBNR claims liability from December 31, 2021 through June 30, 2022 is summarized below: Amount Balance as of December 31, 2021 $ 33,078 Incurred related to: Current period 215,332 Prior periods (1,466) 213,866 Paid related to: Current period (152,738) Prior periods (29,159) (181,897) Balance as of June 30, 2022 $ 65,047
Schedule of Remaining Performance Obligation	The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of June 30, 2022, is expected to be recognized as follows: Less than Greater Total As of June 30, 2022 $ 15,193 $ 27,002 $ 42,195

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Components of Operating Lease Costs	The components of operating lease costs were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating lease costs $ 13,609 $ 7,856 $ 26,613 $ 15,189 Variable lease costs 2,449 1,222 4,496 2,533 Total lease costs $ 16,058 $ 9,078 $ 31,109 $ 17,722
Supplemental Cash Flow Information	Supplemental Cash Flow Information Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 12,398 $ 7,973 $ 24,464 $ 15,828 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 14,477 $ 19,336 $ 32,726 $ 35,422
Lease Term and Discount Rate	Lease Term and Discount Rate June 30, December 31, 2022 2021 Weighted-average remaining lease term (in years) 7.96 8.02 Weighted-average discount rate 6.61 % 6.55 %
Future Minimum Lease Payments Under Non-cancellable Operating Leases	Future minimum lease payments under non-cancellable operating leases as of June 30, 2022 were as follows (excluding the effect of lease incentives to be received that are recorded in other current assets of $16,353 which serve to reduce total lease payments): June 30, 2022 Remainder of 2022 $ 27,674 2023 58,264 2024 56,601 2025 52,821 2026 49,304 Thereafter 183,019 Total lease payments 427,683 Less: interest (99,622) Total lease liabilities $ 328,061

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Purchase Price Components	The purchase price components are summarized in the following table: Consideration in 1Life common stock (1) $ 1,313,312 Cash consideration (2) 62,881 Stock options of Iora assumed by 1Life towards pre-combination services (3) 48,643 Total Purchase Price $ 1,424,836 (1) Represents the fair value of 53,583 shares of 1Life common stock transferred as consideration consisting of 53,146 shares issued and 437 shares to be issued to former Iora shareholders for outstanding Iora capital stock based on 77,687 Iora shares with the Exchange Ratio of 0.69 for a share of Iora and 1Life's stock price of $24.51 as of the closing date. The fair value of the 53,583 shares transferred as consideration was determined on the basis of the closing market price of the Company's common stock one business day prior to the Acquisition Date. (2) Included in the cash consideration are: • $5,993 for the settlement of vested phantom stock awards and cash bonuses contingent on the completion of the merger. Iora's unvested phantom stock awards, to the extent they relate to post-combination services, will be paid out and expensed as they vest subsequent to the acquisition and will be treated as stock-based compensation expense. • $30,253 of loans made by the Company to Iora prior to the Acquisition Date. • $5,391 of repayment of the existing Silicon Valley Bank (“SVB”) loan, which was not legally assumed as part of the merger. • The remainder of the cash consideration primarily relates to transaction expenses incurred by Iora and paid by the Company as of the closing date. (3) Represents the fair value of Iora’s equity awards assumed by 1Life for pre-combination services. Pursuant to the terms of the Iora Merger Agreement, Iora’s outstanding equity awards that are vested and unvested as of the effective time of the merger were replaced by 1Life equity awards with the same terms and conditions. The vested portion of the fair value of 1Life’s replacement equity awards issued represents consideration transferred, while the unvested portion represents post-combination compensation expense based on the vesting terms of the equity awards. The awards that include a provision for accelerated vesting upon a change of control are included in the vested consideration. The fair value of the stock options of Iora assumed by 1Life was determined by using a Black-Scholes option pricing model with the applicable assumptions as of the Acquisition Date. The fair value of the unvested stock awards, for which post-combination service is required, will be recorded as share-based compensation expense over the respective vesting period of each award. See Note 10, "Stock-Based Compensation".
Preliminary Purchase Allocation	The following table presents the preliminary purchase price allocation recorded in the Company's unaudited condensed consolidated balance sheet as of the Acquisition Date, updated to reflect measurement period adjustments as further described below: Cash and cash equivalents acquired $ 17,808 Accounts receivable, net 20,166 Prepaid expenses and other current assets 3,043 Restricted cash 2,069 Property and equipment, net 29,565 Right-of-use assets 70,249 Intangible assets, net 363,031 Other assets (1) 7,405 Total assets 513,336 Accounts payable 1,974 Accrued expenses 9,819 Deferred revenue, current 5,989 Operating lease liabilities, current 6,617 Operating lease liabilities, non-current 63,558 Deferred revenue, non-current 24,316 Deferred income taxes 80,537 Other non-current liabilities (1) 13,888 Total liabilities 206,698 Net assets acquired 306,638 Estimated merger consideration 1,424,836 Estimated goodwill attributable to merger $ 1,118,198 (1) Included in the other assets was an escrow asset of $2,034 related to 1Life common stock held by a third-party escrow agent to be released to the former stockholders of Iora, less any amounts that would be necessary to satisfy any then pending and unsatisfied or unresolved claim for indemnification for any 1Life indemnifiable loss pursuant to the indemnity provisions of the Iora Merger Agreement. A corresponding indemnification liability of $9,600 was recorded in other non-current liabilities in the Company's unaudited condensed consolidated balance sheet. During the six months ended June 30, 2022, a reduction in escrow asset and indemnification liability of $1,013 and $3,383, respectively was recorded as part of the measurement period adjustment. The indemnification asset is subject to remeasurement at each reporting date due to changes to the underlying value of the escrow shares until the shares are released from escrow, with the remeasurement adjustment reported in the Company's condensed consolidated statement of operations as interest and other expense. During the three and six months ended June 30, 2022, the fair value of the escrow asset had declined and the unrealized loss recorded was $841 and $3,118, respectively.
Identifiable Intangible Assets Acquired	Identifiable intangible assets are comprised of the following: Preliminary Fair Value Estimated Useful Life (in years) Intangible Asset: Medicare Advantage contracts - existing geographies $ 298,000 9 CMS Direct Contracting contract - existing geographies 52,000 9 Trade name: Iora 13,031 3 Total $ 363,031
Material Adjustments to the Unaudited Pro Forma Results	The table below reflects the impact of material adjustments to the unaudited pro forma results for the three and six months ended June 30, 2021 that are directly attributable to the acquisition: Three Months Ended June 30, Six Months Ended June 30, Material Adjustments 2021 2021 (Decrease) / increase to expense as result of transaction costs $ (1,953) $ (5,190) (Decrease) / increase to expense as result of amortization and depreciation expenses 11,536 23,077 (Decrease) / increase to expense as a result of stock-based compensation costs 607 1,305 (Decrease) / increase to expense as result of changes in tax effects $ (3,144) $ (8,053)
Unaudited Pro Forma Information	The unaudited pro forma information presented below is for informational purposes only and is not necessarily indicative of our condensed consolidated results of operations of the combined business had the acquisition actually occurred at the beginning of fiscal year 2020 or the results of our future operations of the combined businesses. Three Months Ended June 30, Six Months Ended June 30, 2021 2021 Revenue $ 204,673 $ 388,293 Net Loss $ (74,752) $ (137,126)

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill balances as of June 30, 2022 and December 31, 2021 were as follows: Goodwill Balance as of December 31, 2021 $ 1,147,464 Goodwill recorded in connection with acquisition 11,800 Measurement period adjustments (2,085) Balance as of June 30, 2022 $ 1,157,179
Schedule of Intangible Assets and Accumulated Amortization	The following summarizes the Company’s intangible assets and accumulated amortization as of June 30, 2022: June 30, 2022 Original Cost Accumulated Amortization Net Book Value Medicare Advantage contracts - existing geographies $ 298,000 $ (27,593) $ 270,407 CMS Direct Contracting contract - existing geographies 52,000 (4,815) 47,185 Trade name: Iora 13,031 (3,620) 9,411 Customer relationships 8,121 (799) 7,322 Total intangible assets $ 371,152 $ (36,827) $ 334,325 The following summarizes the Company’s intangible assets and accumulated amortization as of December 31, 2021: December 31, 2021 Original Cost Accumulated Amortization Net Book Value Medicare Advantage contracts - existing geographies $ 298,000 $ (11,037) $ 286,963 CMS Direct Contracting contract - existing geographies 52,000 (1,926) 50,074 Trade name: Iora 13,031 (1,448) 11,583 Customer relationships 3,921 (383) 3,538 Total intangible assets $ 366,952 $ (14,794) $ 352,158
Estimated Future Amortization Expense of Intangible Assets	As of June 30, 2022, estimated future amortization expense related to intangible assets were as follows: June 30, 2022 Remainder of 2022 $ 22,149 2023 44,297 2024 42,818 2025 39,880 2026 39,880 Thereafter 145,301 Total $ 334,325

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Net Carrying Amount of Convertible Senior Notes	The net carrying amount of the 2025 Notes was as follows: June 30, December 31, 2022 2021 Liabilities: Principal $ 316,250 $ 316,250 Unamortized issuance costs (5,468) (6,406) Net carrying amount $ 310,782 $ 309,844
Summary of Interest Expense Recognized Related to Convertible Senior Notes	The following table sets forth the interest expense recognized related to the 2025 Notes: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Contractual interest expense $ 2,372 $ 2,372 $ 4,744 $ 4,744 Amortization of issuance costs 468 468 937 937 Total interest expense related to the 2025 Notes $ 2,840 $ 2,840 $ 5,681 $ 5,681

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	The following table summarizes stock option activity under the Plans: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2021 28,312 $ 19.32 7.57 $ 192,955 Granted 1,819 12.11 Exercised (1,403) 3.88 Canceled (630) 14.57 Outstanding as of June 30, 2022 28,098 $ 19.73 7.26 $ 37,185 Options exercisable as of June 30, 2022 12,228 $ 6.34 5.84 $ 35,355 Options vested and expected to vest as of June 30, 2022 18,179 $ 8.85 6.59 $ 37,157
Schedule of Additional Information Relating to Tranche	The following table presents additional information relating to each tranche of the Performance Stock Option: Tranche Stock Price Milestone Number of Options Tranche 1 $55 per share 1,330 Tranche 2 $70 per share 1,995 Tranche 3 $90 per share 2,660 Tranche 4 $110 per share 2,660
Summary of RSU Activity	The following table summarizes restricted stock unit activity under the 2020 Plan: Number of Grant Date Unvested and outstanding as of December 31, 2021 3,249 $ 27.90 Granted 8,929 9.83 Vested (521) 31.94 Canceled and forfeited (734) 17.56 Unvested and outstanding as of June 30, 2022 10,923 $ 13.63
Summary of Stock-Based Compensation Expense	Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Sales and marketing $ 1,325 $ 964 $ 2,268 $ 1,987 General and administrative 31,011 25,368 66,987 50,673 Total $ 32,336 $ 26,332 $ 69,255 $ 52,660

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share were calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss $ (93,809) $ (41,287) $ (184,668) $ (80,605) Denominator: Weighted average common shares outstanding — basic and diluted 194,488 136,788 193,774 137,045 Net loss per share — basic and diluted $ (0.48) $ (0.30) $ (0.95) $ (0.59)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: As of June 30, 2022 2021 Options to purchase common stock 28,098 25,754 Unvested restricted stock 10,922 2,053 2025 Notes (1) 7,117 7,117 Shares held in special indemnity escrow account in connection with Iora acquisition 405 — 46,542 34,924

Nature of the Business and Ba_3

Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Billions		6 Months Ended
	Jul. 21, 2022	Jun. 30, 2022	Jul. 20, 2022
Subsequent Event | Amazon
Restricted Cash and Cash Equivalents Items [Line Items]
Aggregate purchase consideration	$ 3.9
Amazon Merger | Subsequent Event
Restricted Cash and Cash Equivalents Items [Line Items]
Stock price (in usd per share)			$ 18
Minimum
Restricted Cash and Cash Equivalents Items [Line Items]
Duration of restriction on cash and cash equivalents		1 year
Maximum
Restricted Cash and Cash Equivalents Items [Line Items]
Duration of restriction on cash and cash equivalents		8 years

Nature of the Business and Ba_4

Nature of the Business and Basis of Presentation - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 184,748	$ 341,971	$ 503,238	$ 112,975
Restricted cash, current (included in other current assets)	180	282	119	119
Restricted cash, non-current	3,785	3,801	1,895	1,911
Total cash, cash equivalents, and restricted cash	$ 188,713	$ 346,054	$ 505,252	$ 115,005

Nature of the Business and Ba_5

Nature of the Business and Basis of Presentation - Summary of Customers Representing 10% or More of Accounts Receivables (Details) - Customer Concentration Risk - Accounts Receivable, Net	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Customer F
Product Information [Line Items]
Concentration risk, percentage	45%	38%
Customer I
Product Information [Line Items]
Concentration risk, percentage	17%	23%

Nature of the Business and Ba_6

Nature of the Business and Basis of Presentation - Summary of Customers Representing 10% or More of Net Revenue (Details) - Customer Concentration Risk - Net Revenue	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022
Customer A
Product Information [Line Items]
Concentration risk, percentage		12%
Customer F
Product Information [Line Items]
Concentration risk, percentage		12%
Customer I
Product Information [Line Items]
Concentration risk, percentage	27%		28%
Customer J
Product Information [Line Items]
Concentration risk, percentage	17%		15%

Variable Interest Entities (Det

Variable Interest Entities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Variable Interest Entity [Line Items]
Current assets	$ 560,332	$ 613,027
Current liabilities	$ 216,481	202,109
Variable Interest Entity, Primary Beneficiary | PCs
Variable Interest Entity [Line Items]
Term of arrangement, renewal period	1 year
Current assets	$ 191,665	129,474
Current liabilities	$ 120,995	$ 115,744
Variable Interest Entity, Primary Beneficiary | PCs | Minimum
Variable Interest Entity [Line Items]
Term of arrangement, period	10 years
Variable Interest Entity, Primary Beneficiary | PCs | Maximum
Variable Interest Entity [Line Items]
Term of arrangement, period	20 years

Fair Value Measurements and I_3

Fair Value Measurements and Investments - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	$ 162,874	$ 111,671
U.S. Treasury obligations | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	129,403	58,232
U.S. Treasury obligations | Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		48,296
Foreign government bonds | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		5,012
Commercial paper | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	33,471	48,427
Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	116,118	315,817
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	278,992	475,784
Recurring | U.S. Treasury obligations | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	129,403	58,232
Recurring | U.S. Treasury obligations | Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		48,296
Recurring | Foreign government bonds | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		5,012
Recurring | Commercial paper | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	33,471	48,427
Recurring | Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	116,118	315,817
Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	245,521	422,345
Recurring | Level 1 | U.S. Treasury obligations | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	129,403	58,232
Recurring | Level 1 | U.S. Treasury obligations | Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		48,296
Recurring | Level 1 | Foreign government bonds | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0
Recurring | Level 1 | Commercial paper | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring | Level 1 | Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	116,118	315,817
Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	33,471	53,439
Recurring | Level 2 | U.S. Treasury obligations | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring | Level 2 | U.S. Treasury obligations | Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0
Recurring | Level 2 | Foreign government bonds | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		5,012
Recurring | Level 2 | Commercial paper | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	33,471	48,427
Recurring | Level 2 | Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0	0
Recurring | Level 3 | U.S. Treasury obligations | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring | Level 3 | U.S. Treasury obligations | Long-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0
Recurring | Level 3 | Foreign government bonds | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0
Recurring | Level 3 | Commercial paper | Short-term Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	0	0
Recurring | Level 3 | Money market fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0	$ 0

Fair Value Measurements and I_4

Fair Value Measurements and Investments - Additional Information (Details) - Convertible Senior Notes Due 2025 - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2020	May 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate principal amount outstanding	$ 316,250	$ 316,250
Interest rate	3%		3%	3%
Convertible notes fair value	$ 262,858	$ 288,461

Fair Value Measurements and I_5

Fair Value Measurements and Investments - Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost	$ 184,748	$ 341,971	$ 503,238	$ 112,975
Marketable securities, Gross unrealized gains (losses)	(1,531)	(193)
Total cash equivalents and marketable securities, Amortized cost	280,523	475,977
Total cash equivalents and marketable securities, Fair value	278,992	475,784
Short-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost	164,405	111,733
Marketable securities, Gross unrealized gains (losses)	(1,531)	(62)
Marketable securities, Fair value	162,874	111,671
U.S. Treasury obligations | Short-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost	130,934	58,293
Marketable securities, Gross unrealized gains (losses)	(1,531)	(61)
Marketable securities, Fair value	129,403	58,232
U.S. Treasury obligations | Long-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost		48,427
Marketable securities, Gross unrealized gains (losses)		(131)
Marketable securities, Fair value		48,296
Foreign government bonds | Short-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost		5,013
Marketable securities, Gross unrealized gains (losses)		(1)
Marketable securities, Fair value		5,012
Commercial paper | Short-term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Marketable securities, Amortized cost	33,471	48,427
Marketable securities, Gross unrealized gains (losses)	0	0
Marketable securities, Fair value	33,471	48,427
Cash Equivalents
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost	116,118	315,817
Cash equivalents, Fair value	116,118	315,817
Money market fund
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents, Amortized cost	116,118	315,817
Cash equivalents, Fair value	$ 116,118	$ 315,817

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Net revenue:	$ 255,839	$ 120,416	$ 509,941	$ 241,768
Medicare revenue
Disaggregation of Revenue [Line Items]
Net revenue:	131,594	0	259,016	0
Capitated revenue
Disaggregation of Revenue [Line Items]
Net revenue:	128,521	0	253,151	0
Fee-for-service and other revenue
Disaggregation of Revenue [Line Items]
Net revenue:	3,073	0	5,865	0
Commercial revenue
Disaggregation of Revenue [Line Items]
Net revenue:	124,245	120,416	250,925	241,768
Partnership revenue
Disaggregation of Revenue [Line Items]
Net revenue:	63,401	56,126	124,336	111,057
Net fee-for-service revenue
Disaggregation of Revenue [Line Items]
Net revenue:	35,740	43,416	77,254	87,878
Membership revenue
Disaggregation of Revenue [Line Items]
Net revenue:	25,104	20,874	49,335	41,070
Grant Income
Disaggregation of Revenue [Line Items]
Net revenue:	$ 0	$ 0	$ 0	$ 1,763

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Net Patient Service Revenue by Source (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Net revenue:	$ 255,839	$ 120,416	$ 509,941	$ 241,768
Net fee-for-service revenue
Disaggregation of Revenue [Line Items]
Net revenue:	35,740	43,416	77,254	87,878
Commercial and government third-party payers | Commercial and government third-party payers
Disaggregation of Revenue [Line Items]
Net revenue:	31,122	39,608	67,728	81,843
Patients, including self-pay, insurance co-pays and deductibles | Patients, including self-pay, insurance co-pays and deductibles
Disaggregation of Revenue [Line Items]
Net revenue:	$ 4,618	$ 3,808	$ 9,526	$ 6,035

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Net revenue	$ 255,839	$ 120,416	$ 509,941	$ 241,768
Contract with customer, liability, revenue recognized	25,021	20,041	32,448	26,187
Deferred revenue recognized related to variable consideration	5,296		5,296
Contract with customer liability related to variable consideration non-current	4,103		4,103
Accounts receivable, net	153,155		153,155		$ 103,498
Capitated accounts payable, net	1,680		1,680		7,220
Capitated accounts receivable, net
Disaggregation of Revenue [Line Items]
Accounts receivable, net	32,278		32,278		$ 23,903
Grant Income
Disaggregation of Revenue [Line Items]
Net revenue	0	$ 0	0	$ 1,763
Grant Income | CARES Act | COVID-19
Disaggregation of Revenue [Line Items]
Net revenue	$ 0		$ 0

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Contract Assets and Deferred Revenue (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 153,155	$ 103,498
Contract asset (included in other current assets)	291	458
Deferred revenue	83,419	77,245
Capitated accounts receivable, net
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	32,278	23,903
All other accounts receivable, net
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 120,877	$ 79,595

Revenue Recognition - Capitated

Revenue Recognition - Capitated Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accounts Receivable, After Allowance For Credit Loss [Roll Forward]
IBNR claims liability	$ (65,047)	$ (33,078)
Accounts receivable, net	153,155	103,498
Capitated accounts receivable
Accounts Receivable, After Allowance For Credit Loss [Roll Forward]
Accounts receivable	91,561	56,384
IBNR claims liability	(57,286)	(32,320)
Other adjustments	(1,997)	(161)
Accounts receivable, net	$ 32,278	$ 23,903

Revenue Recognition - Capitat_2

Revenue Recognition - Capitated Accounts Payable, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Capitated accounts (receivable), payable	$ (6,245)	$ 5,483
IBNR claims liability	7,761	1,438
Other adjustments	164	299
Capitated accounts payable, net	$ 1,680	$ 7,220

Revenue Recognition - Activity

Revenue Recognition - Activity in IBNR Claims (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance at beginning of period	$ 33,078
Incurred related to:
Current period	215,332
Prior periods	(1,466)
Incurred	213,866
Paid related to:
Current period	(152,738)
Prior periods	(29,159)
Paid	(181,897)
Balance at end of period	$ 65,047

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Remaining Performance Obligation (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 42,195
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 15,193
Revenue remaining performance obligation, expected timing of satisfaction, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 27,002
Revenue remaining performance obligation, expected timing of satisfaction, period

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Prepaid Expenses and Other Current Assets
Lessee, Lease, Description [Line Items]
Lease incentives	$ 16,353
Minimum
Lessee, Lease, Description [Line Items]
Operating leases, options to extend leases term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Operating leases, options to extend leases term	7 years

Leases - Components of Operatin

Leases - Components of Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating lease costs	$ 13,609	$ 7,856	$ 26,613	$ 15,189
Variable lease costs	2,449	1,222	4,496	2,533
Total lease costs	$ 16,058	$ 9,078	$ 31,109	$ 17,722

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 12,398	$ 7,973	$ 24,464	$ 15,828
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$ 14,477	$ 19,336	$ 32,726	$ 35,422

Leases - Lease Term and Discoun

Leases - Lease Term and Discount Rate (Details)	Jun. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term (in years)	7 years 11 months 15 days	8 years 7 days
Weighted-average discount rate	6.61%	6.55%

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments Under Non-cancellable Operating Leases (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Leases [Abstract]
Remainder of 2022	$ 27,674
2023	58,264
2024	56,601
2025	52,821
2026	49,304
Thereafter	183,019
Total lease payments	427,683
Less: interest	(99,622)
Total lease liabilities	$ 328,061

Business Combinations - Acquisi

Business Combinations - Acquisition of Iora, Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	Sep. 01, 2021	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Common stock and stock options assumed			$ 5,541	$ 0
Cash consideration			10,451	$ 9,695
Goodwill		$ 1,157,179	1,157,179		$ 1,147,464
Measurement period adjustments			$ (2,085)
Iora
Business Acquisition [Line Items]
Aggregate purchase consideration	$ 1,424,836
Cash consideration	62,881
Goodwill	1,118,198
Acquired intangibles	363,031
Measurement period adjustments		$ 285
Deferred tax liability	80,537
Iora | Stock Options
Business Acquisition [Line Items]
Common stock and stock options assumed	48,643
Iora | Common Stock
Business Acquisition [Line Items]
Common stock and stock options assumed	$ 1,313,312

Business Combinations - Purchas

Business Combinations - Purchase Price Components (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Sep. 01, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Common stock and stock options assumed		$ 5,541	$ 0
Cash consideration		$ 10,451	$ 9,695
Common stock, shares issued		195,154,000		191,722,000
Iora
Business Acquisition [Line Items]
Common stock, shares issued	77,687,000
Iora
Business Acquisition [Line Items]
Cash consideration	$ 62,881
Total Purchase Price	$ 1,424,836
Number of shares issued	53,583,000
Number of shares to be issued or reserved for issuance	53,146,000
Number of shares issuable	437,000
Number of shares to be converted per each acquiree share	0.69
Stock price (in usd per share)	$ 24.51
Payment for settlement of vested phantom stock awards and cash bonuses contingent on completion of the merger	$ 5,993
Loan advances	30,253
Iora | Credit Facility
Business Acquisition [Line Items]
Debt assumed and repaid	5,391
Iora | Stock Options
Business Acquisition [Line Items]
Common stock and stock options assumed	48,643
Iora | Common Stock
Business Acquisition [Line Items]
Common stock and stock options assumed	$ 1,313,312

Business Combinations - Prelimi

Business Combinations - Preliminary Purchase Price Allocation (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Dec. 31, 2021	Sep. 01, 2021
Business Acquisition [Line Items]
Estimated goodwill attributable to merger	$ 1,157,179	$ 1,157,179	$ 1,147,464
Iora
Business Acquisition [Line Items]
Cash and cash equivalents acquired				$ 17,808
Accounts receivable, net				20,166
Prepaid expenses and other current assets				3,043
Restricted cash				2,069
Property and equipment, net				29,565
Right-of-use assets				70,249
Intangible assets, net				363,031
Other assets				7,405
Total assets				513,336
Accounts payable				1,974
Accrued expenses				9,819
Deferred revenue, current				5,989
Operating lease liabilities, current				6,617
Operating lease liabilities, non-current				63,558
Deferred revenue, non-current				24,316
Deferred income taxes				80,537
Other non-current liabilities				13,888
Total liabilities				206,698
Net assets acquired				306,638
Estimated merger consideration				1,424,836
Estimated goodwill attributable to merger				1,118,198
Escrow deposit				2,034
Indemnification liability				$ 9,600
Measurement period adjustment on escrow asset		(1,013)
Measurement period adjustment on indemnification liability		(3,383)
Unrealized loss on fair value adjustment of escrow asset	$ 841	$ 3,118

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired (Details) - Iora $ in Thousands	Sep. 01, 2021 USD ($)
Business Acquisition [Line Items]
Preliminary Fair Value	$ 363,031
Medicare Advantage contracts - existing geographies
Business Acquisition [Line Items]
Preliminary Fair Value	$ 298,000
Estimated Useful Life (in years)	9 years
CMS Direct Contracting contract - existing geographies
Business Acquisition [Line Items]
Preliminary Fair Value	$ 52,000
Estimated Useful Life (in years)	9 years
Trade name: Iora
Business Acquisition [Line Items]
Preliminary Fair Value	$ 13,031
Estimated Useful Life (in years)	3 years

Business Combinations - Loan Ag

Business Combinations - Loan Agreement (Details) - Iora - Credit Facility $ in Thousands	Sep. 01, 2021 USD ($)
Business Acquisition [Line Items]
Debt assumed and repaid	$ 5,391
Debt prepayment penalty	$ 50

Business Combinations - Adjustm

Business Combinations - Adjustments to Pro Forma Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Transaction costs
Business Acquisition [Line Items]
Net loss	$ (1,953)	$ (5,190)
Amortization and depreciation expenses
Business Acquisition [Line Items]
Net loss	11,536	23,077
Stock-based compensation costs
Business Acquisition [Line Items]
Net loss	607	1,305
Change in tax effects
Business Acquisition [Line Items]
Net loss	$ (3,144)	$ (8,053)

Business Combinations - Unaudit

Business Combinations - Unaudited Pro Forma (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Revenue	$ 204,673	$ 388,293
Net Loss	$ (74,752)	$ (137,126)

Business Combinations - Other A

Business Combinations - Other Acquisitions (Details) $ in Thousands		6 Months Ended		12 Months Ended
	Apr. 14, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) business_acquired
Business Acquisition [Line Items]
Cash consideration		$ 10,451	$ 9,695
Common stock and stock options assumed		5,541	$ 0
Goodwill		$ 1,157,179		$ 1,147,464
Customer relationships | Minimum
Business Acquisition [Line Items]
Useful life				3 years
Customer relationships | Maximum
Business Acquisition [Line Items]
Useful life				7 years
PeakMed Colorado Springs, LLC
Business Acquisition [Line Items]
Aggregate purchase consideration	$ 17,354
Cash consideration	10,938
Contingent consideration	875
Goodwill	11,800
Acquired intangibles	$ 4,200
Useful life	9 years
PeakMed Colorado Springs, LLC | Common Stock
Business Acquisition [Line Items]
Common stock and stock options assumed	$ 5,541
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Cash consideration				$ 9,908
Goodwill				$ 5,880
Number of acquisitions | business_acquired				3
Series of Individually Immaterial Business Acquisitions | Customer relationships
Business Acquisition [Line Items]
Acquired intangibles				$ 3,921

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) reportingUnit	Jun. 30, 2021 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Number of reporting units | reportingUnit			1
Goodwill impairments	$ 0	$ 0	$ 0	$ 0
Goodwill [Roll Forward]
Balance as of December 31, 2021			1,147,464,000
Goodwill recorded in connection with acquisition			11,800,000
Measurement period adjustments			(2,085,000)
Balance as of June 30, 2022	$ 1,157,179,000		$ 1,157,179,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets and Accumulated Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangibles	$ 11,074	$ 88	$ 22,033	$ 88
Finite-Lived Intangible Assets [Line Items]
Original Cost	371,152		371,152		$ 366,952
Accumulated Amortization	(36,827)		(36,827)		(14,794)
Net Book Value	334,325		334,325		352,158
Medicare Advantage contracts - existing geographies
Finite-Lived Intangible Assets [Line Items]
Original Cost	298,000		298,000		298,000
Accumulated Amortization	(27,593)		(27,593)		(11,037)
Net Book Value	270,407		270,407		286,963
CMS Direct Contracting contract - existing geographies
Finite-Lived Intangible Assets [Line Items]
Original Cost	52,000		52,000		52,000
Accumulated Amortization	(4,815)		(4,815)		(1,926)
Net Book Value	47,185		47,185		50,074
Trade name: Iora
Finite-Lived Intangible Assets [Line Items]
Original Cost	13,031		13,031		13,031
Accumulated Amortization	(3,620)		(3,620)		(1,448)
Net Book Value	9,411		9,411		11,583
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Original Cost	8,121		8,121		3,921
Accumulated Amortization	(799)		(799)		(383)
Net Book Value	$ 7,322		$ 7,322		$ 3,538

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Estimated Future Amortization (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2022	$ 22,149
2023	44,297
2024	42,818
2025	39,880
2026	39,880
Thereafter	145,301
Net Book Value	$ 334,325	$ 352,158

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended
	May 31, 2020 USD ($) Tradingday $ / shares shares	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 shares	Jul. 20, 2022 $ / shares	Jun. 30, 2020 USD ($)
Amazon Merger | Subsequent Event
Debt Instrument [Line Items]
Stock price (in usd per share) | $ / shares				$ 18
Convertible Senior Notes Due 2025
Debt Instrument [Line Items]
Face amount | $	$ 275,000				$ 41,250
Interest rate	3%	3%			3%
Proceeds from debt offering | $	$ 306,868
Convertible conversion amount | $	$ 1
Debt converted to common stock (in shares) | shares	22.5052000	7,117,000	7,117,000
Debt instrument conversion price (in usd per share) | $ / shares	$ 44.43
Number of threshold trading days	20
Number of consecutive trading days	30
Conversion percentage	130%
Debt instrument, repurchase price percentage	100%
Debt issuance costs | $		$ 9,374
Effective interest rate		0.65%
Convertible Senior Notes Due 2025 | Conversion Scenario One
Debt Instrument [Line Items]
Number of threshold trading days	20
Number of consecutive trading days	30
Conversion percentage	130%
Convertible Senior Notes Due 2025 | Conversion Scenario Two
Debt Instrument [Line Items]
Convertible conversion amount | $	$ 1
Number of consecutive trading days	10
Number of business days	5
Percentage applied to product of common stock price and conversion rate	98%

Convertible Senior Notes - Summ

Convertible Senior Notes - Summary of Net Carrying Amount of Liability Component of Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal	$ 316,250	$ 316,250
Unamortized issuance costs	(5,468)	(6,406)
Net carrying amount	$ 310,782	$ 309,844

Convertible Senior Notes - Su_2

Convertible Senior Notes - Summary of Interest Expense Recognized Related to Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Contractual interest expense	$ 2,372	$ 2,372	$ 4,744	$ 4,744
Amortization of issuance costs	468	468	937	937
Total interest expense related to the 2025 Notes	$ 2,840	$ 2,840	$ 5,681	$ 5,681

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Incentive Plan, Additional Information (Details) - 2020 Equity Incentive Plan - shares shares in Thousands	1 Months Ended
	Jan. 31, 2020	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future grants		6,975
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Term of options granted	10 years
Common Stock Reserve Auto Increase
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of number of shares of common stock outstanding	4%

Stock-Based Compensation - 2020

Stock-Based Compensation - 2020 Employee Stock Purchase Plan, Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 32,336	$ 26,332	$ 69,255	$ 52,660
2020 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Offering period			six-month
Number of shares available for future grants	7,046,000		7,046,000
Stock based compensation expense	$ 177	$ 591	$ 602	$ 1,212

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Number of Options
Outstanding as of beginning of period (in shares) | shares	28,312
Granted (in shares) | shares	1,819
Exercised (in shares) | shares	(1,403)
Canceled (in shares) | shares	(630)
Outstanding as of end of period (in shares) | shares	28,098	28,312
Number of Options, Options exercisable as of end of period (in shares) | shares	12,228
Number of Options, Option vested and expected to vest as of end of period (in shares) | shares	18,179
Weighted- Average Exercise Price
Outstanding as of beginning of period (in usd per share) | $ / shares	$ 19.32
Granted (in usd per share) | $ / shares	12.11
Exercised (in usd per share) | $ / shares	3.88
Canceled (in usd per share) | $ / shares	14.57
Outstanding as of end of period (in usd per share) | $ / shares	19.73	$ 19.32
Weighted-Average Exercise Price, Options exercisable (in usd per share) | $ / shares	6.34
Weighted-Average Exercise Price, Options vested and expected to vest (in usd per share) | $ / shares	$ 8.85
Weighted-Average Remaining Contractual Term (Years), Outstanding	7 years 3 months 3 days	7 years 6 months 25 days
Weighted-Average Remaining Contractual Term (Years), Options exercisable	5 years 10 months 2 days
Weighted-Average Remaining Contractual Term (Years), Options vested and expected to vest	6 years 7 months 2 days
Aggregate Intrinsic Value, Outstanding | $	$ 37,185	$ 192,955
Aggregate Intrinsic Value, Options exercisable | $	35,355
Aggregate Intrinsic Value, Options vested and expected to vest | $	$ 37,157

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock Options, Additional information (Details) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) shares	Jun. 30, 2021 USD ($)	Dec. 31, 2020 tranche shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense related to service-based options	$ 19,403	$ 14,805	$ 19,403	$ 14,805
Weighted-average period over which unrecognized compensation cost is expected to be recognized			1 year 6 months	1 year 9 months 18 days
Fair value of options granted	11,598	50	$ 11,598	$ 12,218
Granted (in shares) | shares			1,819
Stock based compensation expense	32,336	$ 26,332	$ 69,255	$ 52,660
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) | shares					8,645
Number of tranches | tranche					4
Vesting period					7 years
Achievement of pre-determined increases, period					90 days
Aggregate stock-based compensation expense if service-based vesting conditions are met			197,469
Stock based compensation expense	13,661		27,750
Unamortized stock-based compensation expense	$ 109,202		$ 109,202

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumed Equity Awards (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Sep. 01, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock and stock options assumed				$ 5,541	$ 0
Stock based compensation expense		$ 32,336	$ 26,332	$ 69,255	$ 52,660
Assumed Equity Plan | Equity Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of assumed awards	$ 60,856
Common stock and stock options assumed	52,662
Stock based compensation expense	$ 8,194

Stock-Based Compensation - Tran

Stock-Based Compensation - Tranches of Performance Stock Option (Details) - Performance Shares shares in Thousands	12 Months Ended
	Dec. 31, 2020 $ / shares shares
Tranche 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) | $ / shares	$ 55
Number of Options (in shares) | shares	1,330
Tranche 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) | $ / shares	$ 70
Number of Options (in shares) | shares	1,995
Tranche 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) | $ / shares	$ 90
Number of Options (in shares) | shares	2,660
Tranche 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Price Milestone (in usd per share) | $ / shares	$ 110
Number of Options (in shares) | shares	2,660

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Details) - 2020 Plan - Restricted Stock Unit shares in Thousands	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Number of Shares
Unvested and outstanding as of beginning of period (in shares) | shares	3,249
Granted (in shares) | shares	8,929
Vested (in shares) | shares	(521)
Canceled and forfeited (in shares) | shares	(734)
Unvested and outstanding as of end of period (in shares) | shares	10,923
Grant Date Fair Value
Unvested and outstanding as of beginning of period (in usd per share) | $ / shares	$ 27.90
Granted (in usd per share) | $ / shares	9.83
Vested (in usd per share) | $ / shares	31.94
Canceled and forfeited (in usd per share) | $ / shares	17.56
Unvested and outstanding as of end of period (in usd per share) | $ / shares	$ 13.63

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 32,336	$ 26,332	$ 69,255	$ 52,660
Tax benefits related to stock based awards	797	2,248	2,735	32,642
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	1,325	964	2,268	1,987
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 31,011	$ 25,368	$ 66,987	$ 50,673

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Provision for (benefit from) income taxes	$ (6,916)	$ (4,040)	$ (13,648)	$ 159
Effective income tax rate			6.90%	8.90%
Income tax benefit from change in valuation allowance			$ 6,930

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net loss	$ (93,809)	$ (90,859)	$ (41,287)	$ (39,318)	$ (184,668)	$ (80,605)
Denominator:
Weighted average common shares outstanding — basic (in shares)	194,488		136,788		193,774	137,045
Weighted average common shares outstanding — diluted (in shares)	194,488		136,788		193,774	137,045
Net loss per share — basic (in usd per share)	$ (0.48)		$ (0.30)		$ (0.95)	$ (0.59)
Net loss per share — diluted (in usd per share)	$ (0.48)		$ (0.30)		$ (0.95)	$ (0.59)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	1 Months Ended	6 Months Ended
	May 31, 2020	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		46,542,000	34,924,000
Convertible Senior Notes Due 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Debt converted to common stock (in shares)	22.5052000	7,117,000	7,117,000
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		28,098,000	25,754,000
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		10,922,000	2,053,000
Shares held in special indemnity escrow account in connection with Iora acquisition
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		405,000	0

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands	1 Months Ended	3 Months Ended
	May 31, 2018 Plaintiff	Jun. 30, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Number of plaintiffs | Plaintiff	2
Litigation liabiity		$ 11,500
Insurers committed amount		5,950
Litigation settlement amount		$ 5,550

Note Receivable (Details)

Note Receivable (Details) - USD ($) $ in Thousands	Sep. 01, 2021	Jun. 21, 2021
Iora
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan advances	$ 30,253
Iora
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable outstanding	$ 30,000
Maturity period following the earliest of certain maturity dates in the SVB Facility		90 days
Interest rate on notes receivable		10%
Iora | Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable outstanding		$ 75,000

Proposed Acquisition by Amazon

Proposed Acquisition by Amazon (Details) - Subsequent Event	Jul. 21, 2022 USD ($)	Jul. 20, 2022 USD ($) tranche $ / shares
Amazon Merger
Subsequent Event [Line Items]
Stock price (in usd per share) | $ / shares		$ 18
Maximum borrowings		$ 300,000,000
Number of tranches | tranche		10
Maximum borrowings per month		$ 30,000,000
Maturity date		24 months
Amazon
Subsequent Event [Line Items]
Aggregate purchase consideration	$ 3,900,000,000